PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

PrINVOQ®

Upadacitinib extended-release tablets

Extended-release tablets, 15 mg upadacitinib, oral

Selective immunosuppressant

AbbVie Corporation
8401 Trans-Canada Highway
St-Laurent, Qc H4S 1Z1

Date of Preparation:
December 23, 2019

Submission Control No: 223734
# TABLE OF CONTENTS

## PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3

1. INDICATIONS ........................................................................................................... 3
   1.1 Pediatrics (<18 years of age): ................................................................. 3
   1.2 Geriatrics (≥65 years of age): ................................................................. 3

2. CONTRAINDICATIONS ....................................................................................... 3

3. SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................. 4

4. DOSAGE AND ADMINISTRATION .................................................................... 5
   4.1 Dosing Considerations ........................................................................... 5
   4.2 Recommended Dose and Dosage Adjustment ....................................... 5
   4.3 Administration ....................................................................................... 6
   4.4 Missed Dose ......................................................................................... 6

5. OVERDOSAGE .................................................................................................... 6

6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ............ 7

7. WARNINGS AND PRECAUTIONS .................................................................... 7
   7.1 Special Populations ............................................................................... 11

8. ADVERSE REACTIONS .................................................................................... 12
   8.1 Adverse Drug Reaction Overview ....................................................... 12
   8.2 Clinical Trial Adverse Drug Reactions ................................................. 14
   8.3 Less Common Clinical Trial Adverse Drug Reactions (<1%) .............. 17
   8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data ................................................................. 17

9. DRUG INTERACTIONS ..................................................................................... 19
   9.1 Overview ............................................................................................... 19
   9.2 Drug-Drug Interactions ....................................................................... 19
   9.3 Drug-Food Interactions ....................................................................... 22
   9.4 Drug-Herb Interactions ....................................................................... 22
   9.5 Drug-Laboratory Test Interactions ....................................................... 22

10. ACTION AND CLINICAL PHARMACOLOGY ............................................... 23
   10.1 Mechanism of Action ......................................................................... 23
   10.2 Pharmacodynamics ........................................................................... 23
   10.3 Pharmacokinetics ............................................................................... 24

11. STORAGE, STABILITY AND DISPOSAL ....................................................... 25

12. SPECIAL HANDLING INSTRUCTIONS ....................................................... 26

## PART II: SCIENTIFIC INFORMATION ................................................................... 27

13. PHARMACEUTICAL INFORMATION ................................................................. 27

14. CLINICAL TRIALS ........................................................................................ 28
   14.1 Trial Design and Study Demographics .............................................. 28
   14.2 Study Results ..................................................................................... 31

15. NON-CLINICAL TOXICOLOGY ..................................................................... 41

PATIENT MEDICATION INFORMATION ................................................................. 43
PART I: HEALTH PROFESSIONAL INFORMATION

1. INDICATIONS

RINVOQ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

RINVOQ may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).

Limitations of Use: RINVOQ should not be used in combination with other Janus kinase (JAK) inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine [see WARNINGS AND PRECAUTIONS (7)].

1.1 Pediatrics (<18 years of age):

The safety and efficacy of RINVOQ in children and adolescents aged 0 to less than 18 years have not been established. No data are available, therefore, RINVOQ should not be used in this pediatric patient population [see DOSAGE AND ADMINISTRATION (4.2), WARNINGS AND PRECAUTIONS (7.1.3), and ACTION AND CLINICAL PHARMACOLOGY (10.3)].

1.2 Geriatrics (≥65 years of age):

Caution should be used when treating geriatric patients with RINVOQ. There are limited data in patients 75 years of age and older. In clinical studies of rheumatoid arthritis patients treated with RINVOQ, there was an increased incidence of serious adverse events in patients 65 years of age and older [see DOSAGE AND ADMINISTRATION (4.2), WARNINGS AND PRECAUTIONS (7.1.4), and ACTION AND CLINICAL PHARMACOLOGY (10.3)].

2. CONTRAINDICATIONS

RINVOQ is contraindicated in patients who are hypersensitive to upadacitinib or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see the DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING (6) section.
3. **SERIOUS WARNINGS AND PRECAUTIONS BOX**

---

**Serious Warnings and Precautions**

**SERIOUS INFECTIONS**

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death [see **WARNINGS AND PRECAUTIONS (7)** and **ADVERSE REACTIONS (8.2)**]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

If a serious infection develops, interrupt RINVOQ until the infection is controlled.

Reported infections include:

- Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before RINVOQ use and during therapy. Treatment for latent infection should be considered prior to RINVOQ use.
- Invasive fungal infections, including cryptococcosis and pneumocystosis.
- Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

Treatment with RINVOQ should not be initiated in patients with active infections including chronic or localized infections.

The risks and benefits of treatment with RINVOQ should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with RINVOQ, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy [see **WARNINGS AND PRECAUTIONS (7)**].

**MALIGNANCIES**

Lymphoma and other malignancies have been observed in patients treated with RINVOQ [see **WARNINGS AND PRECAUTIONS (7)**].

**THROMBOSIS**

Thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated with Janus kinase inhibitors, including RINVOQ, for inflammatory conditions. Many of these adverse events were serious and some resulted in death. Consider the risks and benefits prior to treating patients who may be at increased risk. Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately [see **WARNINGS AND PRECAUTIONS (7)**].

---
4. DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- RINVOQ should not be initiated in patients with active infections including chronic or localized infections [see WARNINGS AND PRECAUTIONS (7)].

- RINVOQ should not be initiated in patients with an absolute lymphocyte count (ALC) less than 500 cells/mm³, absolute neutrophil count (ANC) less than 1000 cells/mm³, or hemoglobin level less than 8 g/dL [see WARNINGS AND PRECAUTIONS (7)].

- RINVOQ should not be initiated in patients with severe hepatic impairment (Child-Pugh C) [see ACTION AND CLINICAL PHARMACOLOGY (10.3)].

- RINVOQ should not be used concomitantly with other potent immunosuppressants. Combined use of RINVOQ with other potent immunosuppressant drugs (e.g. azathioprine, cyclosporine, tacrolimus), other JAK inhibitors, or biologic DMARDs has not been studied in rheumatoid arthritis patients. There is a risk of additive immunosuppression when RINVOQ is co-administered with potent immunosuppressant drugs [see WARNINGS AND PRECAUTIONS (7) and DRUG INTERACTIONS (9.2)].

- RINVOQ should be used with caution in patients receiving chronic treatment with strong CYP3A inhibitors. Upadacitinib exposure is increased when co-administered with strong CYP3A inhibitors (such as ketoconazole) [see DRUG INTERACTIONS (9.1)].

- Co-administration of RINVOQ with strong CYP3A4 inducers is not recommended. Upadacitinib exposure is decreased when co-administered with strong CYP3A inducers (such as rifampin), which may lead to reduced therapeutic effect of RINVOQ [see WARNINGS AND PRECAUTIONS (7) and DRUG INTERACTIONS (9.1)].

4.2 Recommended Dose and Dosage Adjustment

The recommended oral dose of RINVOQ is 15 mg once daily.

RINVOQ may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.

RINVOQ may be given with or without food [see ACTION AND CLINICAL PHARMACOLOGY (10.3)].

Dose Interruption

RINVOQ treatment should be interrupted if a patient develops a serious infection until the infection is controlled [see WARNINGS AND PRECAUTIONS (7)].

RINVOQ treatment should be interrupted for management of laboratory abnormalities as described in Table 1.
Table 1. Recommended Dose Interruptions for Laboratory Abnormalities

<table>
<thead>
<tr>
<th>Laboratory measure</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absolute Neutrophil Count (ANC)</td>
<td>Treatment should be interrupted if ANC is less than 1000 cells/mm³ and may be restarted once ANC returns above this value</td>
</tr>
<tr>
<td>Absolute Lymphocyte Count (ALC)</td>
<td>Treatment should be interrupted if ALC is less than 500 cells/mm³ and may be restarted once ALC returns above this value</td>
</tr>
<tr>
<td>Hemoglobin (Hb)</td>
<td>Treatment should be interrupted if Hb is less than 8 g/dL and may be restarted once Hb returns above this value</td>
</tr>
<tr>
<td>Hepatic transaminases</td>
<td>Treatment should be temporarily interrupted if drug-induced liver injury is suspected</td>
</tr>
</tbody>
</table>

**Dosing in special populations**

**Pediatrics (<18 years of age):** RINVOQ should not be used in this patient population. The safety and efficacy of RINVOQ in children and adolescents aged 0 to less than 18 years have not been established. No data are available, therefore, RINVOQ should not be used in this pediatric patient population [see INDICATIONS (1.1), WARNINGS AND PRECAUTIONS (7.1.3), and ACTION AND CLINICAL PHARMACOLOGY (10.3)].

**Geriatric (≥65 years of age):** No dose adjustment is required in patients aged 65 years and older [see WARNINGS AND PRECAUTIONS (7.1.4), and ACTION AND CLINICAL PHARMACOLOGY (10.3)].

**Hepatic Impairment:** RINVOQ should not be used in patients with severe hepatic impairment (Child Pugh C). The use of RINVOQ has not been studied in patients with severe hepatic impairment. No dose adjustment is required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment [see ACTION AND CLINICAL PHARMACOLOGY (10.3)].

**Renal Impairment:** No dose adjustment is required in patients with mild, moderate, or severe renal impairment. The use of RINVOQ has not been studied in subjects with end stage renal disease [see ACTION AND CLINICAL PHARMACOLOGY (10.3)].

**4.3 Administration**

RINVOQ is to be taken orally once daily with or without food and may be taken at any time of the day. RINVOQ tablets should be swallowed whole. RINVOQ should not be split, crushed, or chewed.

**4.4 Missed Dose**

If a dose of RINVOQ is missed, it should be taken as soon as possible. The subsequent dose should be taken at the regularly scheduled time.

**5. OVERDOSAGE**

Upadacitinib was administered in clinical trials up to doses equivalent in daily AUC (area under the curve) to 60 mg extended-release once daily. Adverse events were comparable to those seen at lower doses and no specific toxicities were identified. Approximately 90% of upadacitinib in the systemic circulation is eliminated within 24 hours of dosing (within the range of doses evaluated in clinical studies). In case of an overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.
For management of a suspected drug overdose, contact your regional Poison Control Centre.

6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

RINVOQ is available as 15 mg extended-release tablets.

RINVOQ 15 mg extended-release tablets are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. The tablets are provided in bottles. Each bottle contains 30 tablets.

Listing of Non-Medicinal Ingredients

Each tablet contains the following inactive ingredients: colloidal silicon dioxide, ferrosoferric oxide (E172), hypromellose, iron oxide red (E172), magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc, tartaric acid, and titanium dioxide.

The tablets do not contain gluten.

7. WARNINGS AND PRECAUTIONS

Please see the SERIOUS WARNINGS AND PRECAUTIONS BOX at the beginning of Part I: Health Professional Information.

Cardiovascular

Thrombosis: Thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated for inflammatory conditions with JAK inhibitors, including RINVOQ [see ADVERSE REACTIONS (8.2)]. Many of these adverse events were serious and some resulted in death.

Consider the risks and benefits of RINVOQ treatment prior to treating patients who may be at increased risk of thrombosis. If symptoms of thrombosis occur, patients should be evaluated promptly and treated appropriately.

Endocrine and Metabolism

Treatment with RINVOQ was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol [see ADVERSE REACTIONS (8.4)]. Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined.

Patients should be monitored 12 weeks after initiation of treatment and thereafter according to the clinical guidelines for hyperlipidemia. Manage patients according to clinical guidelines for the management of hyperlipidemia [see WARNINGS AND PRECAUTIONS (7), Monitoring and Laboratory Tests].
Gastrointestinal

Gastrointestinal Perforations: Events of gastrointestinal perforation have been reported in clinical studies with RINVOQ [see ADVERSE REACTIONS (8.2)], although the role of JAK inhibition in these events is not known. In these studies, many patients with rheumatoid arthritis were receiving background therapy with nonsteroidal anti-inflammatory drugs (NSAIDs).

RINVOQ should be used with caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking concomitant NSAIDs and/or corticosteroids). Patients presenting with new onset abdominal symptoms should be evaluated promptly for early identification of gastrointestinal perforation.

Hematologic

Anemia: Decreases in hemoglobin levels to less than 8 g/dL were reported in RINVOQ clinical studies [see ADVERSE REACTIONS (8.4)]. Evaluate hemoglobin prior to initiation of RINVOQ and thereafter according to routine patient management. Do not initiate and interrupt RINVOQ treatment in patients with a low hemoglobin level (i.e., less than 8 g/dL) [see DOSAGE AND ADMINISTRATION (4.1, 4.2) and WARNINGS AND PRECAUTIONS (7), Monitoring and Laboratory Tests].

Lymphopenia: Absolute Lymphocyte Counts (ALC) less than 500 cells/mm³ were reported in RINVOQ clinical studies [see ADVERSE REACTIONS (8.4)]. Evaluate lymphocyte counts prior to initiation of RINVOQ and thereafter according to routine patient management. Do not initiate and interrupt RINVOQ treatment in patients with a low lymphocyte count (i.e., less than 500 cells/mm³) [see DOSAGE AND ADMINISTRATION (4.1, 4.2) and WARNINGS AND PRECAUTIONS (7), Monitoring and Laboratory Tests].

Neutropenia: Treatment with RINVOQ was associated with an increased incidence of neutropenia (ANC less than 1000 cells/mm³) [see ADVERSE REACTIONS (8.4)]. Evaluate neutrophil counts prior to initiating RINVOQ and thereafter according to routine patient management. Do not initiate and interrupt RINVOQ treatment in patients with a low neutrophil count (i.e., ANC less than 1000 cells/mm³) [see DOSAGE AND ADMINISTRATION (4.1, 4.2) and WARNINGS AND PRECAUTIONS (7), Monitoring and Laboratory Tests].

Hepatic

Treatment with RINVOQ was associated with an increased incidence of liver enzyme elevation compared to placebo [see ADVERSE REACTIONS (8.4)]. Increases to ≥3X the upper limit of normal (ULN) for both alanine transaminase (ALT) and aspartate transaminase (AST) were the more frequently reported, but increases to ≥5X and ≥10X ULN were also observed in patients treated with RINVOQ in clinical trials. Unconfirmed drug induced liver injury (DILI) was observed in four patients receiving upadacitinib in clinical trials, including 2 patients receiving RINVOQ. Upadacitinib was discontinued in 3 cases and was continued without interruption in one patient receiving RINVOQ.

Liver enzymes should be evaluated before initiating RINVOQ treatment and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of DILI. If increases in ALT or AST are observed during routine patient management and DILI is suspected, RINVOQ should be interrupted until this diagnosis is excluded [see DOSAGE AND ADMINISTRATION (4.2) and WARNINGS AND PRECAUTIONS (7), Monitoring and Laboratory Tests].
Although patients with active hepatitis B or C infection were excluded from clinical trials, cases of hepatitis B virus reactivation were still reported in patients enrolled in the clinical studies of RINVOQ. Screening for viral hepatitis and monitoring for reactivation should be performed in accordance with clinical guidelines before starting and during therapy with RINVOQ. If hepatitis B virus DNA is detected while receiving RINVOQ, a liver specialist should be consulted [see WARNINGS AND PRECAUTIONS (7), Infections].

The use of RINVOQ has not been studied in patients with severe hepatic impairment and therefore, RINVOQ should not be used in these patients [see DOSAGE AND ADMINISTRATION (4.2) and ACTION AND CLINICAL PHARMACOLOGY (10.3)].

**Immune**

RINVOQ should not be used concomitantly with other potent immunosuppressants. Concomitant use of RINVOQ with other potent immunosuppressants (such as azathioprine, cyclosporine, tacrolimus), biologic DMARDs, or other JAK inhibitors has not been evaluated in clinical studies. There is a risk of additive immunosuppression when RINVOQ is co-administered with potent immunosuppressant drugs [see DOSAGE AND ADMINISTRATION (4.1) and DRUG INTERACTIONS (9.2)].

**Immunizations**

No data are available on the response to vaccination with live or inactivated vaccines in patients receiving RINVOQ. Live or attenuated vaccines should not be used immediately prior to or during RINVOQ therapy. Prior to initiating RINVOQ treatment, patients should be brought up to date with all immunizations, including prophylactic zoster vaccinations, in agreement with current immunization guidelines. The interval between live vaccinations and initiation of RINVOQ therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents.

**Infections**

**Serious Infections**

Serious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported with RINVOQ included pneumonia and cellulitis [see ADVERSE REACTIONS (8.2)]. Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis were reported with RINVOQ.

RINVOQ should not be initiated in patients with active infections including chronic or localized infections. Consider the risks and benefits of treatment prior to initiating RINVOQ in patients:

- With chronic or recurrent infection
- Who have been exposed to tuberculosis
- With a history of a serious or an opportunistic infection
- Who have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or
- With underlying conditions that may predispose them to infection.
Closely monitor patients for the development of signs and symptoms of infection during and after treatment with RINVOQ. Interrupt RINVOQ if a patient develops a serious or opportunistic infection. A patient who develops a new infection during treatment with RINVOQ should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be initiated, the patient should be closely monitored, and RINVOQ should be interrupted if the patient is not responding to antimicrobial therapy. Do not resume RINVOQ treatment until the infection is controlled.

**Tuberculosis**

Patients should be screened for tuberculosis (TB) before starting RINVOQ therapy. RINVOQ should not be given to patients with active TB. Anti-TB therapy should be considered prior to initiation of RINVOQ in patients with previously untreated latent TB or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection.

Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient.

Monitor patients for the development of signs and symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.

**Viral reactivation**

Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster) and hepatitis B virus reactivation, were reported in clinical studies with RINVOQ [see ADVERSE REACTIONS (8.2)]. If a patient develops herpes zoster, consider temporarily interrupting RINVOQ until the episode resolves.

Screening for viral hepatitis and monitoring for reactivation should be performed in accordance with clinical guidelines before starting and during therapy with RINVOQ. Patients who were positive for hepatitis C antibody and hepatitis C virus RNA, were excluded from clinical studies. Patients who were positive for hepatitis B surface antigen or hepatitis B virus DNA were excluded from clinical studies. However, cases of hepatitis B reactivation were still reported in patients enrolled in the clinical studies of RINVOQ. If hepatitis B virus DNA is detected while receiving RINVOQ, a liver specialist should be consulted.

**Malignancies**

Malignancies were observed in clinical studies of RINVOQ [see ADVERSE REACTIONS (8.2)]. Consider the risks and benefits of RINVOQ treatment prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing RINVOQ in patients who develop a malignancy.

**Non-Melanoma Skin Cancer (NMSC)**

NMSCs have been reported in patients treated with RINVOQ. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.

**Musculoskeletal**

Treatment with RINVOQ was associated with dose-related increases in creatine phosphokinase (CPK) [see ADVERSE REACTIONS (8.4)]. CPK levels should be checked in patients with symptoms of muscle weakness and/or muscle pain to evaluate for evidence of rhabdomyolysis.
Monitoring and Laboratory Tests

**Hematology:** Lymphocyte counts, neutrophil counts, and hemoglobin should be evaluated before initiating RINVOQ treatment and thereafter according to routine patient management. Treatment should not be initiated and should be interrupted in patients with low lymphocyte count (ALC less than 500 cells/mm\(^3\)), low neutrophil count (ANC less than 1000 cells/mm\(^3\)), or low hemoglobin level (less than 8 g/dL) [see DOSAGE AND ADMINISTRATION (4.1, 4.2) and WARNINGS AND PRECAUTIONS (7), Hematologic].

**Lipids:** Assessment of lipid parameters should be performed 12 weeks after initiation of RINVOQ treatment and thereafter according to the clinical guidelines for hyperlipidemia. Patients should be managed according to clinical guidelines for the management of hyperlipidemia [see WARNINGS AND PRECAUTIONS (7), Endocrine and Metabolism].

**Liver Enzyme Elevations:** Liver enzymes should be evaluated before initiating RINVOQ treatment and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. If increases in ALT or AST are observed during routine patient management and drug-induced liver injury is suspected, RINVOQ treatment should be interrupted until this diagnosis is excluded [see DOSAGE AND ADMINISTRATION (4.2) and WARNINGS AND PRECAUTIONS (7), Hepatic].

**Sexual Health**

**Reproduction – Embryo-Fetal Toxicity:** Based on findings in animal studies, RINVOQ may cause fetal harm when administered to a pregnant woman. Administration of upadacitinib to rats and rabbits during organogenesis caused increases in fetal malformations [see NON-CLINICAL TOXICOLOGY (15)]. Pregnant women should be advised of the potential risk to a fetus. Females of reproductive potential should be advised to use effective contraception during treatment with RINVOQ and for 4 weeks following completion of therapy [see WARNINGS AND PRECAUTIONS (7.1.1)].

7.1 Special Populations

7.1.1 Pregnant Women

RINVOQ should not be used during pregnancy. There are limited human data on the use of upadacitinib in pregnant women. There are no adequate and well-controlled studies to assess the use of RINVOQ in pregnant women. Studies in animals have shown reproductive toxicity [see NON-CLINICAL TOXICOLOGY (15)]. In animal embryo-fetal developmental studies, upadacitinib was teratogenic in rats and rabbits with dose-related increases in skeletal malformations in rat fetuses and an increased incidence of cardiovascular malformations in rabbit fetuses when exposed in utero. Increased post-implantation loss was seen in rabbits and decreased fetal body weights were observed in both rats and rabbits. The effect of upadacitinib on human fertility has not been evaluated. Animal studies do not indicate effects with respect to fertility [see NON-CLINICAL TOXICOLOGY (15)].

Based on animal studies, upadacitinib has the potential to adversely affect a developing fetus and may cause embryo-fetal harm when administered to pregnant women. Women of reproductive potential should be advised to use effective contraception during treatment and for 4 weeks following the final dose of RINVOQ. If the patient becomes pregnant while taking RINVOQ, inform the patient of the potential hazard to a fetus.
7.1.2 Breast-feeding

RINVOQ should not be used during breast-feeding. It is unknown if upadacitinib is excreted in human milk. Lactation studies have not been conducted to assess the presence of upadacitinib in human milk, the effects on the breastfed infant, or the effects on milk production. Available pharmacodynamic/toxicological data in animals have shown excretion of upadacitinib in milk. Following administration of upadacitinib to lactating rats, upadacitinib exposure was approximately 30-fold greater in milk than in maternal plasma. Approximately 97% of drug-related material in milk was parent drug.

A risk to newborns/infants cannot be excluded. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because of the potential for serious adverse reactions in the breastfed infant, patients should be advised not to breast-feed during treatment with RINVOQ, and for 6 days (approximately 10 half-lives) after the last dose.

7.1.3 Pediatrics (<18 years of age)

The safety and efficacy of RINVOQ in children and adolescents aged 0 to less than 18 years have not been established. No data are available, therefore, RINVOQ should not be used in this pediatric patient population [see INDICATIONS (1.1), DOSAGE AND ADMINISTRATION (4.2), and ACTION AND CLINICAL PHARMACOLOGY (10.3)].

7.1.4 Geriatrics (≥65 years of age)

Caution should be used when treating geriatric patients with RINVOQ. There are limited data in patients 75 years of age and older. In five phase 3 clinical studies, 518 rheumatoid arthritis patients treated with RINVOQ were 65 years of age and older, including 78 patients 75 years of age and older. Although no differences in effectiveness were observed between these patients and younger patients, there was an increased incidence of serious adverse events, severe adverse events, adverse drug reactions, and adverse events leading to RINVOQ discontinuation in patients ≥65 years of age [see INDICATIONS (1.2), DOSAGE AND ADMINISTRATION (4.2), and ACTION AND CLINICAL PHARMACOLOGY (10.3)].

8. ADVERSE REACTIONS

8.1 Adverse Drug Reaction Overview

A total of 3833 patients with rheumatoid arthritis were treated with upadacitinib in the phase 3 clinical studies, of whom 2806 were exposed for at least one year.

In five phase 3 studies, 2630 patients received at least 1 dose of RINVOQ 15 mg, of whom 1860 were exposed for at least one year. In Studies I, II, III and V, 1213 patients received at least 1 dose of RINVOQ 15 mg, of whom 986 patients were exposed for at least one year, and 1203 patients received at least 1 dose of upadacitinib 30 mg, of whom 946 were exposed for at least one year.

The following four safety datasets were integrated from the five phase 3 clinical studies and were used to evaluate the adverse drug reaction profile of RINVOQ 15 mg once daily (QD):

1) Placebo-controlled studies: Studies III, IV, and V were integrated to represent the safety of RINVOQ 15 mg (n = 1035) in comparison to placebo (n = 1042) for up to 12 to 14 weeks following treatment initiation.
2) Studies III and V were integrated to represent safety through 12 weeks for placebo (n = 390), RINVOQ 15 mg (n = 385), and upadacitinib 30 mg (n = 384). Study IV did not include the 30 mg dose and therefore, safety data for upadacitinib 30 mg can only be compared to placebo and RINVOQ 15 mg data from pooling Studies III and V.

3) Methotrexate (MTX)-controlled studies: Studies I and II were integrated to represent safety through 12 to 14 weeks for MTX (n = 530), RINVOQ 15 mg (n = 534), and upadacitinib 30 mg (n = 529).

4) 12-Month exposure dataset: Studies I, II, III, and V were integrated to represent the long-term safety of RINVOQ 15 mg (n = 1213) and upadacitinib 30 mg (n = 1203).

Exposure adjusted incidence rates were adjusted by study for all the adverse events (AEs) reported.

In the placebo-controlled period of the studies, there were no deaths in patients treated with RINVOQ 15 mg compared to 0.2% of patients treated with placebo. In MTX-controlled studies, the percentage of deaths in patients receiving RINVOQ 15 mg monotherapy, upadacitinib 30 mg monotherapy, and MTX monotherapy was 0.2%, 0.6%, and 0.2%, respectively. In Study I, the overall incidence rates of death for the RINVOQ 15 mg monotherapy, upadacitinib 30 mg monotherapy, and MTX monotherapy groups were 1 per 100 patient-years, 1.8 per 100 patient-years, and 0.3 per 100 patient-years, respectively. In the 12-Month exposure dataset, the overall incidence rates of death were 0.5 per 100 patient-years for the RINVOQ 15 mg group and 0.9 per 100 patient-years for the upadacitinib 30 mg group. The most common causes of death in the upadacitinib clinical program were cardiovascular related.

In the placebo-controlled period of the studies, serious adverse events (SAEs) were reported in a higher percentage of patients treated with RINVOQ 15 mg (3.4%) and upadacitinib 30 mg (4.9%) compared to patients treated with placebo (1.8%). The overall incidence rate of SAEs in the 12-Month exposure dataset was higher in the upadacitinib 30 mg group (16.2 per 100 patient-years) compared to the RINVOQ 15 mg group (13.1 per 100 patient-years). The most common SAEs in patients treated with upadacitinib (incidence rate of ≥0.5 per 100 patient-years) included pneumonia, osteoarthritis, and pulmonary embolism.

In the placebo-controlled period of the studies, treatment emergent adverse events were reported in a higher percentage of patients treated with RINVOQ 15 mg (56%) compared to patients treated with placebo (48%). The most commonly reported AEs occurring in ≥2% of patients treated with RINVOQ 15 mg and reported at a higher incidence versus placebo were upper respiratory tract infection, nasopharyngitis, urinary tract infection, nausea, bronchitis, blood creatine phosphokinase (CPK) increased, cough, and back pain.

In the placebo-controlled period of Studies III, IV, and V, adverse drug reactions (ADRs, according to investigator assessed causality) were reported in a higher percentage of patients treated with RINVOQ 15 mg (27%) compared to patients treated with placebo (20%). The most common ADRs reported in ≥2% of patients treated with RINVOQ 15 mg and reported at a higher percentage versus placebo were upper respiratory tract infections, nausea, CPK elevation, and cough. In the 12-Month exposure dataset, the overall incidence rate of ADRs was higher in the upadacitinib 30 mg group (79.9 per 100 patient-years) compared to the RINVOQ 15 mg group (65.8 per 100 patient-years). The most common ADRs in patients treated with RINVOQ 15 mg (incidence rate of ≥1 per 100 patient-years), other than the ADRs presented under Clinical Trial Adverse Drug Reactions (8.2), included upper respiratory tract infection, urinary tract infection, herpes zoster, nasopharyngitis, bronchitis, sinusitis, nausea, and headache.
In the placebo-controlled period of the studies, AEs leading to discontinuation of treatment were reported in 2% of patients treated with placebo, and 2.8% of patients treated with RINVOQ 15 mg. The overall incidence rate of AEs leading to discontinuation of treatment in the 12-Month exposure dataset was higher in the upadacitinib 30 mg group (11.4 per 100 patient-years) compared to the RINVOQ 15 mg group (8.0 per 100 patient-years). The most common AEs leading to discontinuation from treatment were infections. The most common infections (incidence rate of ≥0.5 per 100 patient-years) resulting in discontinuation of treatment were pneumonia and herpes zoster.

8.2 Clinical Trial Adverse Drug Reactions

_Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates._

The adverse reactions occurring in ≥1% of patients treated with RINVOQ 15 mg once daily during the double-blind, placebo-controlled portion of the three placebo-controlled studies (Studies III, IV, and V) for up to 12 to 14 weeks are listed below in Table 2.

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Placebo&lt;sup&gt;a&lt;/sup&gt;</th>
<th>RINVOQ 15 mg&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Adalimumab&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper respiratory tract infection (URTI)*</td>
<td>9.5</td>
<td>13.5</td>
<td>8.0</td>
</tr>
<tr>
<td>Nausea</td>
<td>2.2</td>
<td>3.5</td>
<td>2.4</td>
</tr>
<tr>
<td>Blood creatine phosphokinase (CPK) increased</td>
<td>0.9</td>
<td>2.5</td>
<td>0.3</td>
</tr>
<tr>
<td>Cough</td>
<td>1.0</td>
<td>2.2</td>
<td>1.2</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>0.2</td>
<td>1.8</td>
<td>0.3</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>0</td>
<td>1.2</td>
<td>0.3</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>0.2</td>
<td>1.1</td>
<td>1.2</td>
</tr>
</tbody>
</table>

<sup>a</sup> Studies III, IV, and V  
<sup>b</sup> Study IV  
*URTI includes: acute sinusitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinusitis, tonsillitis, viral upper respiratory tract infection

The frequency of herpes zoster, lymphopenia, CPK elevations and ALT/AST elevations were higher with RINVOQ 15 mg compared to adalimumab.
Specific Adverse Reactions

Infections

In the placebo-controlled studies (Studies III, IV, and V), infections were reported in 218 patients (95.7 per 100 patient-years) in the placebo group versus 284 patients (127.8 per 100 patient-years) in the RINVOQ 15 mg group over 12/14 weeks. In Studies III and V, infections were reported in 99 patients (136.5 per 100 patient-years) in the placebo group, 118 patients (164.5 per 100 patient-years) in the RINVOQ 15 mg group, and 126 patients (180.3 per 100 patient-years) in the upadacitinib 30 mg group over 12 weeks.

In the MTX-controlled studies (Studies I and II), infections were reported in 127 patients (119.5 per 100 patient-years) treated with MTX monotherapy, 104 patients (91.8 per 100 patient-years) treated with RINVOQ 15 mg monotherapy, and 128 patients (115.1 per 100 patient-years) treated with upadacitinib 30 mg monotherapy over 12/14 weeks.

In the 12-Month exposure dataset (Studies I, II, III, and V), infections were reported in 615 patients (83.8 per 100 patient-years) treated with RINVOQ 15 mg and 674 patients (99.7 per 100 patient-years) treated with upadacitinib 30 mg.

Serious Infections

In the placebo-controlled studies (Studies III, IV, and V), serious infections were reported in 6 patients (2.3 per 100 patient-years) treated with placebo and 12 patients (4.6 per 100 patient-years) treated with RINVOQ 15 mg over 12/14 weeks. In Studies III and V, serious infections were reported in 1 patient (1.2 per 100 patient-years) treated with placebo, 2 patients (2.3 per 100 patient-years) treated with RINVOQ 15 mg, and 7 patients (8.2 per 100 patient-years) treated with upadacitinib 30 mg over 12 weeks.

In the MTX-controlled studies (Studies I and II), serious infections were reported in 2 patients (1.6 per 100 patient-years) treated with MTX monotherapy, 3 patients (2.4 per 100 patient-years) treated with RINVOQ 15 mg monotherapy, and 8 patients (6.4 per 100 patient-years) treated with upadacitinib 30 mg monotherapy over 12/14 weeks.

In the 12-Month exposure dataset (Studies I, II, III, and V), serious infections were reported in 38 patients (3.5 per 100 patient-years) treated with RINVOQ 15 mg and 59 patients (5.6 per 100 patient-years) treated with upadacitinib 30 mg.

The most frequently reported serious infections were pneumonia and cellulitis.

Tuberculosis

In the placebo-controlled clinical studies (Studies III, IV, and V), there were no active cases of tuberculosis reported in the placebo, RINVOQ 15 mg, or upadacitinib 30 mg groups over 12/14 weeks.

In the MTX-controlled studies (Studies I and II), there were no active cases of tuberculosis reported in the MTX monotherapy, RINVOQ 15 mg monotherapy, or upadacitinib 30 mg monotherapy groups over 12 weeks.

In the 12-Month exposure dataset (Studies I, II, III, and V), active tuberculosis was reported in 2 patients treated with RINVOQ 15 mg and in 1 patient treated with upadacitinib 30 mg. Cases of extra-pulmonary tuberculosis were reported.
**Opportunistic Infections (excluding tuberculosis)**

In the placebo-controlled studies (Studies III, IV, and V) opportunistic infections were reported in 3 patients (1.2 per 100 patient-years) in the placebo group and 5 patients (1.9 per 100 patient-years) in the RINVOQ 15 mg group over 12/14 weeks. In Studies III and V, opportunistic infections were reported in 1 patient (1.2 per 100 patient-years) in the placebo group, 2 patients (2.3 per 100 patient-years) in the RINVOQ 15 mg group, and 6 patients (7.1 per 100 patient-years) in the upadacitinib 30 mg group over 12 weeks.

In the MTX-controlled studies (Studies I and II), opportunistic infections were reported in 1 patient (0.8 per 100 patient-years) treated with MTX monotherapy, 0 patients treated with RINVOQ 15 mg monotherapy, and 4 patients (3.2 per 100 patient-years) treated with upadacitinib 30 mg monotherapy through 12/14 weeks.

In the 12-Month exposure dataset (Studies I, II, III, and V), opportunistic infections were reported in 7 patients (0.6 per 100 patient-years) treated with RINVOQ 15 mg and 15 patients (1.4 per 100 patient-years) treated with upadacitinib 30 mg.

**Malignancy**

In the placebo-controlled studies (Studies III, IV, and V) malignancies excluding NMSC were reported in 1 patient (0.4 per 100 patient-years) in the placebo group and 1 patient (0.4 per 100 patient-years) in the RINVOQ 15 mg group over 12/14 weeks. In Studies III and V, malignancies excluding NMSC were reported in 0 patients in the placebo group, 1 patient (1.1 per 100 patient-years) in the RINVOQ 15 mg group, and 3 patients (3.5 per 100 patient-years) in the upadacitinib 30 mg group over 12 weeks.

In the MTX-controlled studies (Studies I and II), malignancies excluding NMSC were reported in 1 patient (0.8 per 100 patient-years) treated with MTX monotherapy, 3 patients (2.4 per 100 patient-years) treated with RINVOQ 15 mg monotherapy, and 0 patients treated with upadacitinib 30 mg monotherapy over 12/14 weeks.

In the 12-Month exposure dataset (Studies I, II, III, and V), malignancies excluding NMSC were reported in 13 patients (1.2 per 100 patient-years) treated with RINVOQ 15 mg and 14 patients (1.3 per 100 patient-years) treated with upadacitinib 30 mg.

**Gastrointestinal Perforations**

In the placebo-controlled studies (Studies III, IV, and V), there were no gastrointestinal perforations (based on medical review) reported in patients treated with placebo, RINVOQ 15 mg, or upadacitinib 30 mg over 12/14 weeks.

In the MTX-controlled studies (Studies I and II), there were no cases of gastrointestinal perforations reported in either the RINVOQ 15 mg monotherapy group or the MTX group over 12/14 weeks. Two cases of gastrointestinal perforations were observed in the upadacitinib 30 mg group.

In the 12-Month exposure dataset (Studies I, II, III, and V) gastrointestinal perforations were reported in 1 patient treated with RINVOQ 15 mg and 4 patients treated with upadacitinib 30 mg.
**Thrombosis**

In the placebo-controlled studies (Studies III, IV, and V): In Study IV, venous thrombosis (pulmonary embolism or deep vein thrombosis) was observed in 1 patient in the placebo group and 1 patient in the RINVOQ 15 mg group. In Study V, venous thrombosis was observed in 1 patient treated with RINVOQ 15 mg. There were no observed cases of venous thrombosis reported in Study III. No cases of arterial thrombosis were observed through 12/14 weeks.

In the MTX-controlled studies (Studies I and II): In Study I, venous thrombosis was observed in 1 patient treated with MTX, 0 patients treated with RINVOQ 15 mg, and 1 patient treated with upadacitinib 30 mg through Week 24. In Study I, arterial thrombosis was observed in 1 patient treated with upadacitinib 30 mg through Week 24. In Study II, venous thrombosis was observed in 0 patients treated with MTX monotherapy, 1 patient treated with RINVOQ 15 mg monotherapy, and 0 patients treated with upadacitinib 30 mg monotherapy through Week 14. In Study II, no cases of arterial thrombosis were observed through 12/14 weeks.

In the 12-Month exposure dataset (Studies I, II, III, and V): Venous thrombosis events were reported in 5 patients (0.5 per 100 patient-years) treated with RINVOQ 15 mg and 4 patients (0.4 per 100 patient-years) treated with upadacitinib 30 mg. Arterial thrombosis events were reported in 0 patients treated with RINVOQ 15 mg and 2 patients (0.2 per 100 patient-years) treated with upadacitinib 30 mg.

**8.3 Less Common Clinical Trial Adverse Drug Reactions (<1%)**

Other adverse reactions (other than the adverse reactions listed in Table 2) reported in less than 1% of patients in the RINVOQ 15 mg group and at a higher rate than in the placebo group through Week 12 in the three placebo-controlled studies (Studies III, IV, and V), included pneumonia, herpes zoster, herpes simplex (includes oral herpes), and oral candidiasis.

**8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data**

**Hepatic transaminase elevations**

In the placebo-controlled studies (Studies III, IV, and V) with background DMARDs, for up to 12/14 weeks, alanine transaminase (ALT) and aspartate transaminase (AST) elevations ≥3X upper limit of normal (ULN) in at least one measurement were observed in 2.1% and 1.5% of patients treated with RINVOQ 15 mg and in 1.5% and 0.7% of patients treated with placebo, respectively. In Studies III and V, ALT and AST elevations ≥3X ULN in at least one measurement were observed in 0.8% and 1.0% of patients treated with RINVOQ 15 mg, 1.0% and 0% of patients treated with upadacitinib 30 mg, and in 1.3% and 1.0% of patients treated with placebo, respectively.

In MTX-controlled studies (Studies I and II), for up to 12/14 weeks, ALT and AST elevations ≥3X ULN in at least one measurement were observed in 0.8% and 0.4% of patients treated with RINVOQ 15 mg, 1.7% and 1.3% of patients treated with upadacitinib 30 mg, and in 1.9% and 0.9% of patients treated with MTX, respectively.
Lipid elevations

RINVOQ 15 mg treatment was associated with dose-related increases in total cholesterol, triglycerides, and LDL cholesterol. Upadacitinib was also associated with increases in HDL cholesterol. Elevations in LDL and HDL cholesterol peaked by Week 8 and remained stable thereafter. In controlled studies, for up to 12/14 weeks, changes from baseline in lipid parameters in patients treated with RINVOQ 15 mg and upadacitinib 30 mg, respectively, are summarized below:

- Mean LDL cholesterol increased by 0.38 mmol/L and 0.44 mmol/L.
- Mean HDL cholesterol increased by 0.21 mmol/L and 0.23 mmol/L.
- The mean LDL/HDL ratio remained stable.
- Mean triglycerides increased by 0.15 mmol/L and 0.16 mmol/L.

Creatine phosphokinase (CPK) elevations

In the placebo-controlled studies (Studies III, IV, and V) with backgrounds DMARDs, for up to 12/14 weeks, dose-related increases in creatine phosphokinase (CPK) values were observed. CPK elevations >5X ULN were reported in 1.0% and 0.3% of patients over 12/14 weeks in the RINVOQ 15 mg and placebo groups, respectively. Most elevations >5X ULN were transient and did not require treatment discontinuation. In Studies III and V, CPK elevations >5X ULN were observed in 0.3% of patients treated with placebo, 1.6% of patients treated with RINVOQ 15 mg, and none in patients treated with upadacitinib 30 mg.

Neutropenia

In the placebo-controlled studies (Studies III, IV, and V) with background DMARDs, for up to 12/14 weeks, dose-related decreases in neutrophil counts, below 1000 cells/mm$^3$ in at least one measurement, occurred in 1.1% and <0.1% of patients in the RINVOQ 15 mg and placebo groups, respectively. In Studies III and V, decreases in neutrophil counts below 1000 cells/mm$^3$ in at least one measurement occurred in 0.3% of patients treated with placebo, 1.3% of patients treated with RINVOQ 15 mg, and 2.4% of patients treated with upadacitinib 30 mg. In clinical studies, treatment was interrupted in response to ANC less than 1000 cells/mm$^3$.

Lymphopenia

In the placebo-controlled studies (Studies III, IV, and V) with background DMARDs, for up to 12/14 weeks, dose-related decreases in lymphocyte counts below 500 cells/mm$^3$ in at least one measurement occurred in 0.9% and 0.7% of patients in the RINVOQ 15 mg and placebo groups, respectively. In Studies III and V, decreases in lymphocyte counts below 500 cells/mm$^3$ in at least one measurement occurred in 0.5% of patients treated with placebo, 0.5% of patients treated with RINVOQ 15 mg, and 2.4% of patients treated with upadacitinib 30 mg.

Anemia

In placebo-controlled studies (Studies III, IV, and V) with background DMARDs, for up to 12/14 weeks, hemoglobin decreases below 8 g/dL in at least one measurement occurred in <0.1% of patients in both the RINVOQ 15 mg and placebo groups. In Studies III and V, hemoglobin decreases below 8 g/dL in at least one measurement were observed in 0.3% of patients treated with placebo, and none in patients treated with RINVOQ 15 mg or upadacitinib 30 mg.
9. DRUG INTERACTIONS

9.1 Overview

**In vitro** assessment of interactions

*In vitro* metabolism studies indicated that upadacitinib metabolism is mediated by CYP3A4 with a potential minor contribution from CYP2D6.

*In vitro* studies indicate that upadacitinib does not inhibit or induce the activity of cytochrome P450 (CYP) enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) or the transporters P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, and MATE2K at clinically relevant concentrations.

*In vitro*, upadacitinib is a substrate for the efflux transporters P-gp and BCRP.

9.2 Drug-Drug Interactions

Potential for Other Drugs to Affect the Pharmacokinetics of Upadacitinib

Upadacitinib exposure is increased when co-administered with strong CYP3A4 inhibitors (such as ketoconazole). RINVOQ should be used with caution in patients receiving chronic treatment with strong CYP3A4 inhibitors [see DOSAGE AND ADMINISTRATION (4.1)].

Upadacitinib exposure is decreased when co-administered with strong CYP3A4 inducers (such as rifampin), which may lead to reduced therapeutic effect of RINVOQ. Coadministration of RINVOQ with strong CYP3A4 inducers is not recommended [see DOSAGE AND ADMINISTRATION (4.1)].

The effect of co-administered drugs on upadacitinib plasma exposures is provided in Table 3. The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

<table>
<thead>
<tr>
<th>Co-administered Drug</th>
<th>Regimen of Co-administered Drug</th>
<th>Regimen of Upadacitinib</th>
<th>Referencea</th>
<th>N</th>
<th>Ratio (with/without co-administered drug) No effect = 1.0 (90% CI)b</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methotrexate</td>
<td>10 to 25 mg/week</td>
<td>6 to 24 mg BIDc</td>
<td>CT</td>
<td>11</td>
<td>0.97 (0.86-1.09)</td>
<td>No dose adjustment of RINVOQ is required</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.99 (0.93-1.06)</td>
<td></td>
</tr>
<tr>
<td>Strong CYP3A4 inhibitor: Ketoconazole</td>
<td>400 mg QD x 6 days</td>
<td>3 mg single dosec</td>
<td>CT</td>
<td>11</td>
<td>1.70 (1.55-1.89)</td>
<td>Use RINVOQ with caution if used chronically</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.75 (1.62-1.88)</td>
<td></td>
</tr>
</tbody>
</table>
Methotrexate, inhibitors of organic anion transporting polypeptide 1B (OATP1B) transporters, and pH modifying medications (e.g., antacids or proton pump inhibitors) have no effect on upadacitinib plasma exposures (based on *in vitro* assessments and population pharmacokinetic analyses). CYP2D6 metabolic phenotype had no effect on upadacitinib pharmacokinetics (based on population pharmacokinetic analyses), indicating that inhibitors of CYP2D6 have no clinically relevant effect on upadacitinib exposures.

### Potential for Upadacitinib to Affect the Pharmacokinetics of Other Drugs

The effect of upadacitinib on plasma exposures of other drugs is provided in Table 4. The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).
Table 4. Drug Interactions: Change in Pharmacokinetics of Co-administered Drugs in the Presence of Upadacitinib

<table>
<thead>
<tr>
<th>Co-administered Drug</th>
<th>Regimen of Co-administered Drug</th>
<th>Regimen of Upadacitinib</th>
<th>Reference</th>
<th>N</th>
<th>Ratio (with/without co-administered drug) No effect = 1.0 (90% CI)b</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>AUC</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>10 to 25 mg/week</td>
<td>6 mg to 24 mg BID&lt;sup&gt;c&lt;/sup&gt; x 27 days</td>
<td>CT</td>
<td>11</td>
<td>1.03 (0.86-1.23)</td>
<td>1.14 (0.91-1.43)</td>
</tr>
<tr>
<td>Sensitive CYP1A2 Substrate Caffeine</td>
<td>200 mg single dose</td>
<td>30 mg QD&lt;sup&gt;d&lt;/sup&gt; x 10 days</td>
<td>CT</td>
<td>20</td>
<td>1.13 (1.05-1.22)</td>
<td>1.22 (1.15-1.29)</td>
</tr>
<tr>
<td>Sensitive CYP3A Substrate Midazolam</td>
<td>5 mg single dose</td>
<td>30 mg QD&lt;sup&gt;d&lt;/sup&gt; x 10 days</td>
<td>CT</td>
<td>20</td>
<td>0.74 (0.68-0.80)</td>
<td>0.74 (0.68-0.80)</td>
</tr>
<tr>
<td>Sensitive CYP2D6 Substrate Dextromethorphan</td>
<td>30 mg single dose</td>
<td>30 mg QD&lt;sup&gt;d&lt;/sup&gt; x 10 days</td>
<td>CT</td>
<td>20</td>
<td>1.09 (0.98-1.21)</td>
<td>1.07 (0.95-1.22)</td>
</tr>
<tr>
<td>Sensitive CYP2C9 Substrate S-Warfarin</td>
<td>10 mg single dose</td>
<td>30 mg QD&lt;sup&gt;d&lt;/sup&gt; x 10 days</td>
<td>CT</td>
<td>20</td>
<td>1.07 (1.02-1.11)</td>
<td>1.11 (1.07-1.15)</td>
</tr>
<tr>
<td>Sensitive CYP2C19 Marker 5-OH Omeprazole to Omeprazole metabolic ratio</td>
<td>40 mg single dose omeprazole</td>
<td>30 mg QD&lt;sup&gt;d&lt;/sup&gt; x 10 days</td>
<td>CT</td>
<td>20</td>
<td>--</td>
<td>1.09 (1.00-1.19)</td>
</tr>
<tr>
<td>CYP2B6 Substrate Bupropion</td>
<td>150 mg single dose</td>
<td>30 mg QD&lt;sup&gt;d&lt;/sup&gt; x 10 days</td>
<td>CT</td>
<td>22</td>
<td>0.87 (0.79-0.96)</td>
<td>0.92 (0.87-0.98)</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>5 mg single dose</td>
<td>30 mg QD&lt;sup&gt;d&lt;/sup&gt; x 10 days</td>
<td>CT</td>
<td>12</td>
<td>0.77 (0.63-0.94)</td>
<td>0.67 (0.56-0.82)</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>10 mg single dose</td>
<td>30 mg QD&lt;sup&gt;d&lt;/sup&gt; x 10 days</td>
<td>CT</td>
<td>24</td>
<td>0.88 (0.79-0.97)</td>
<td>0.77 (0.70-0.85)</td>
</tr>
<tr>
<td>Co-administered Drug</td>
<td>Regimen of Co-administered Drug</td>
<td>Regimen of Upadacitinib</td>
<td>Referencea</td>
<td>N</td>
<td>Ratio (with/without co-administered drug) No effect = 1.0 (90% CI)b</td>
<td>Clinical Comment</td>
</tr>
<tr>
<td>----------------------</td>
<td>---------------------------------</td>
<td>-------------------------</td>
<td>------------</td>
<td>---</td>
<td>---------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>0.03 mg single dose</td>
<td>30 mg QDᶜ x 11 days</td>
<td>CT</td>
<td>22</td>
<td>0.96 (0.89-1.02) 1.11 (1.04-1.19)</td>
<td>No dose adjustment of ethinylestradiol is required</td>
</tr>
<tr>
<td>Levonorgestrel</td>
<td>0.15 mg single dose</td>
<td>30 mg QDᶜ x 11 days</td>
<td>CT</td>
<td>22</td>
<td>0.96 (0.87-1.06) 0.96 (0.85-1.07)</td>
<td>No dose adjustment of levonorgestrel is required</td>
</tr>
</tbody>
</table>

Abbreviations: CI = confidence interval; QD = once daily; BID = twice daily

a. Legend: C = case study; CT = clinical trial; T = theoretical (based on simulations)
b. Ratios for C_max and AUC compare co-administration of the medication with upadacitinib vs administration of medication alone. Data represent the point estimates and the corresponding 90% confidence intervals for the difference of the least square means obtained from the repeated measures analyses of the natural logarithms of C_max and AUC.
c. Immediate-release formulation
d. Extended-release formulation

**Immunosuppressants, Other JAK Inhibitors, or Biologic DMARDs**

There is a risk of added immunosuppression when RINVOQ is co-administered with other potent immunosuppressive drugs (e.g., tacrolimus, cyclosporine, azathioprine). The combined use of RINVOQ with other potent immunosuppressants, other JAK inhibitors, or biologic DMARDs has not been studied in rheumatoid arthritis patients and is not recommended [see DOSAGE AND ADMINISTRATION (4.1) and WARNINGS AND PRECAUTIONS (7)].

**9.3 Drug-Food Interactions**

Grapefruit juice inhibits CYP3A-mediated metabolism. RINVOQ should be used with caution when administered concomitantly with grapefruit juice.

**9.4 Drug-Herb Interactions**

St John’s Wort is a CYP3A inducer which may lead to reduced therapeutic effect of RINVOQ. Coadministration of RINVOQ with St John’s Wort is not recommended.

**9.5 Drug-Laboratory Test Interactions**

Interactions with laboratory tests have not been established.
10. ACTION AND CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Upadacitinib is a Janus Kinase (JAK) inhibitor. JAKs are intracellular enzymes that transduce signals from cell surface receptors for cytokines or growth factors involved in a broad range of cellular processes including inflammatory responses, hematopoiesis and immune surveillance. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2).

Upadacitinib inhibits JAKs with a high degree of selectivity against other kinases in the human genome. In cell-free isolated enzyme assays, upadacitinib had greater inhibitory potency at JAK1 relative to JAK2, JAK3 and TYK2 with IC50 values of 43, 120, 2300, and 4700 nM for JAK1, JAK2, JAK3, and TYK2, respectively. However, in human leukocyte cellular assays, upadacitinib inhibited cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 more potently than JAK2/JAK2 mediated STAT phosphorylation. Upadacitinib blocked IL-2 induced (JAK1/JAK3) and IL-6 induced (JAK1/JAK2) STAT phosphorylation at 9 to 13 nM and erythropoietin induced (JAK2/JAK2) STAT phosphorylation at 628 nM. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.

10.2 Pharmacodynamics

Inhibition of IL-6 induced STAT3 and IL-7 induced STAT5 phosphorylation

In healthy volunteers, the administration of upadacitinib (immediate release formulation) resulted in a dose- and concentration-dependent inhibition of IL-6 (JAK1/JAK2)-induced STAT3 and IL-7 (JAK1/JAK3)-induced STAT5 phosphorylation in whole blood. The maximal inhibition was observed 1 hour after dosing which returned to near baseline by the end of dosing interval.

Lymphocytes

Treatment with upadacitinib was associated with a small, transient increase in mean ALC from baseline up to Week 36 which gradually returned to, at or near baseline levels with continued treatment.

Immunoglobulins

In the controlled period of the clinical studies, small decreases from baseline in mean IgG and IgM levels were observed with upadacitinib treatment; however, the mean values at baseline and at all visits were within the normal reference range.

High-sensitivity C-reactive protein (hsCRP)

Treatment with upadacitinib was associated with significant decreases from baseline in mean hsCRP levels as early as Week 1 which were maintained with continued treatment.

Cardiac electrophysiology

The effect of upadacitinib on QTc interval was evaluated in subjects who received single and multiple doses of upadacitinib. Upadacitinib does not prolong QTc interval at therapeutic or supratherapeutic plasma concentrations.
## 10.3 Pharmacokinetics

Upadacitinib is absorbed following administration of the extended-release formulation with a median time to maximum observed plasma concentration ($T_{\text{max}}$) of approximately 2 to 3 hours under fasting conditions and 4 hours under non-fasting conditions. Upadacitinib plasma exposures are proportional to dose over the range of 7.5 mg to 45 mg using the extended-release formulation under fasting conditions. Steady-state plasma concentrations are achieved within 4 days with minimal accumulation after multiple once-daily administrations using the 15 mg extended-release formulation. The pharmacokinetics of upadacitinib do not change over time.

Based on population pharmacokinetic analyses, subjects with rheumatoid arthritis (RA) are estimated to have ~38% lower upadacitinib CL/F compared to healthy subjects. The pharmacokinetic properties of RINVOQ are provided in Table 5.

### Table 5. Summary of RINVOQ’s Pharmacokinetic Parameters in Humans

<table>
<thead>
<tr>
<th></th>
<th>C$_{\text{max, ss}}$ (ng/mL)</th>
<th>$t_{1/2}$ (h)</th>
<th>AUC$_{\text{τ, ss}}$ (ng*hr/mL)</th>
<th>Apparent Oral Clearance (L/h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy Volunteers$^b$</td>
<td>28.1 ± 9.29</td>
<td>8.8 ± 5.4$^d$</td>
<td>251 ± 69.8</td>
<td>64.9 ± 18.77$^c$</td>
</tr>
<tr>
<td>Rheumatoid Arthritis Patients</td>
<td>41.3 ± 7.2$^c$</td>
<td>9-14$^e$</td>
<td>396 ± 141$^c$</td>
<td>40.5 (37)$^c$</td>
</tr>
</tbody>
</table>

a. Legend: $C_{\text{max, ss}}$ = maximum observed drug concentration; $t_{1/2}$ = terminal elimination half-life; AUC$_{\text{τ, ss}}$ = area under the concentration-time curve during one dosing interval at steady state. Values presented are mean ± standard deviation.

b. Summary of pharmacokinetic parameters across Phase 1 studies for 15 mg QD regimen (fasting and non-fasting conditions).

c. The values are from population pharmacokinetic analysis represented as parameter estimate (percent inter-subject variability).

d. Harmonic mean ± pseudo-standard deviation.


**Absorption:** Following oral administration of upadacitinib extended-release formulation, upadacitinib is absorbed with a median $T_{\text{max}}$ of 2 to 4 hours. Coadministration of upadacitinib using the extended-release formulation with a high-fat/high-calorie meal had no clinically relevant effect on upadacitinib exposures (increased AUC$_{\text{inf}}$ by 29% and $C_{\text{max}}$ by 39%). In clinical trials, upadacitinib was administered without regard to meals [see DOSAGE AND ADMINISTRATION (4.2)].

**Distribution:** Upadacitinib is 52% bound to plasma proteins. Upadacitinib partitions similarly between plasma and blood cellular components with a blood to plasma ratio of 1.0.

**Metabolism:** Upadacitinib metabolism is mediated by mainly CYP3A4 with a potential minor contribution from CYP2D6. The pharmacologic activity of upadacitinib is attributed to the parent molecule. In a human radiolabeled study, unchanged upadacitinib accounted for 79% of the total radioactivity in plasma while the main metabolite detected (product of monooxidation followed by glucuronidation) accounted for 13% of the total plasma radioactivity. No active metabolites have been identified for upadacitinib.
**Elimination**: Following single dose administration of \([^{14}C]\)upadacitinib immediate-release solution, upadacitinib was eliminated predominantly as the unchanged parent substance in urine (24%) and feces (38%). Approximately 34% of upadacitinib dose was excreted as metabolites. Upadacitinib mean terminal elimination half-life ranged from 9 to 14 hours.

**Special Populations and Conditions**

**Pediatrics**

The pharmacokinetics of RINVOQ have not been investigated in the pediatric population.

**Geriatrics**

No dose adjustment is required for patients aged >65 years [see DOSAGE AND ADMINISTRATION (4.2)]. Age did not have a clinically meaningful effect on upadacitinib exposure.

**Other Intrinsic Factors**

Sex, body weight, race and ethnicity did not have a clinically meaningful effect on upadacitinib exposure.

**Hepatic Impairment**

Mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment has no clinically relevant effect on upadacitinib exposure. Upadacitinib \(AUC_{\text{inf}}\) was 28% and 24% higher in subjects with mild and moderate hepatic impairment, respectively, compared to subjects with normal liver function. Upadacitinib \(C_{\text{max}}\) was unchanged in subjects with mild hepatic impairment and 43% higher in subjects with moderate hepatic impairment compared to subjects with normal liver function. Upadacitinib was not studied in patients with severe hepatic impairment (Child-Pugh C) and should not be initiated in this patient population [see DOSAGE AND ADMINISTRATION (4.1)].

**Renal Impairment**

Renal impairment has no clinically relevant effect on upadacitinib exposure. Upadacitinib \(AUC_{\text{inf}}\) was 18, 33, and 44% higher in subjects with mild, moderate, and severe renal impairment, respectively, compared to subjects with normal renal function. Upadacitinib \(C_{\text{max}}\) was similar in subjects with normal and impaired renal function.

**11. STORAGE, STABILITY AND DISPOSAL**

**Temperature:**

Store between 2 and 25°C.

**Moisture:**

Store in the original bottle in order to protect from moisture.

**Others:**

Keep out of reach and sight of children.
12. SPECIAL HANDLING INSTRUCTIONS

There are no special handling instructions.
PART II: SCIENTIFIC INFORMATION

13. PHARMACEUTICAL INFORMATION

Proper/Common name: Upadacitinib (INN)

Chemical name: \((3S,4R)\)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1)

Molecular formula and molecular mass:
\[\text{C}_{17}\text{H}_{19}\text{F}_{3}\text{N}_{6}\text{O} \cdot \frac{1}{2} \text{H}_{2}\text{O}\]
(hemihydrate)

\[389.38 \text{ g/mol (hemihydrate)}\]
\[380.38 \text{ g/mol (anhydrate)}\]

Structural formula:

![Structural formula of upadacitinib](image)

Physicochemical properties:
Upadacitinib is a white to light brown powder. The solubility of upadacitinib in water is 38 to less than 0.2 mg/mL across a pH range of 2 to 9 at 37°C.
14. CLINICAL TRIALS

14.1 Trial Design and Study Demographics

The efficacy and safety of RINVOQ (upadacitinib) 15 mg once daily were assessed in five phase 3 randomized, double-blind, multicenter studies in patients with moderately to severely active rheumatoid arthritis and fulfilling the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010 classification criteria (see Table 6). Patients over 18 years of age were eligible to participate. The presence of at least 6 tender and 6 swollen joints and evidence of systemic inflammation based on elevation of high-sensitivity C-reactive protein (hsCRP) was required at baseline. Although other doses have been studied, the recommended dose of RINVOQ is 15 mg once daily.

Baseline demographics were generally similar among the treatment groups in each study and comparable between the studies. Typical of the overall rheumatoid arthritis population, the majority of patients were female and white. The mean (standard deviation [SD]) age ranged from 53.4 (12.73) to 57.1 (11.42) years. The baseline demographics in each study are shown in Table 6.

Table 6. Summary of Patient Demographics for Clinical Trials in Rheumatoid Arthritis

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial Design</th>
<th>Dosage, Route of Administration and Duration</th>
<th>Study Subjects (N)</th>
<th>Age (years) Mean (SD)</th>
<th>Female (%)</th>
<th>Mean Disease Duration (years) (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY I SELECT-EARLY (M13-545)</td>
<td>Randomized, double-blind, active-controlled, multicenter, in MTX-naïve patients</td>
<td>Monotherapy RINVOQ 15 mg Upadacitinib 30 mg MTX Tablets, orally, once daily Main treatment period: 24 weeks</td>
<td>947</td>
<td>53.4 (12.73)</td>
<td>76.3</td>
<td>2.7 (5.38)</td>
</tr>
<tr>
<td>STUDY II SELECT-MONOTHERAPY (M15-555)</td>
<td>Randomized, double-blind, active-controlled, multicenter, in MTX-IR patients</td>
<td>Monotherapy RINVOQ 15 mg Upadacitinib 30 mg MTX Tablets, orally, once daily Main treatment period: 14 weeks</td>
<td>648</td>
<td>54.3 (12.05)</td>
<td>80.7</td>
<td>6.6 (7.58)</td>
</tr>
<tr>
<td>Study #</td>
<td>Trial Design</td>
<td>Dosage, Route of Administration and Duration</td>
<td>Study Subjects (N)</td>
<td>Age (years) Mean (SD)</td>
<td>Female (%)</td>
<td>Mean Disease Duration (years) (SD)</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>------------------------</td>
<td>------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>STUDY III SELECT-NEXT (M13-549)</td>
<td>Randomized, double-blind, placebo-controlled, multicenter, in csDMARD-IRc patients On background csDMARDs</td>
<td>RINVOQ 15 mg Upadacitinib 30 mg Placebo Tablets, orally, once daily Main treatment period: 12 weeks</td>
<td>661</td>
<td>55.7 (11.65)</td>
<td>78.7</td>
<td>7.3 (7.72)</td>
</tr>
<tr>
<td>STUDY IV SELECT-COMPARE (M14-465)</td>
<td>Randomized, double-blind, placebo- and active-controlled, multicenter, in MTX-IRd patients On background MTX</td>
<td>RINVOQ 15 mg Placebo Tablets, orally, once daily Adalimumab 40 mg EOW Main treatment period: 26 weeks</td>
<td>1629</td>
<td>53.9 (12.07)</td>
<td>79.3</td>
<td>8.2 (7.97)</td>
</tr>
<tr>
<td>STUDY V SELECT-BEYOND (M13-542)</td>
<td>Randomized, double-blind, placebo-controlled, multicenter, in bDMARD-IRe patients On background csDMARDs</td>
<td>RINVOQ 15 mg Upadacitinib 30 mg Placebo Tablets, orally, once daily Main treatment period: 12 weeks</td>
<td>499</td>
<td>57.1 (11.42)</td>
<td>83.9</td>
<td>13.2 (9.45)</td>
</tr>
</tbody>
</table>

Abbreviations: bDMARD = biologic disease-modifying antirheumatic drug; csDMARD = conventional synthetic disease-modifying antirheumatic drug; EOW = every other week; IR = inadequate responder, MTX = methotrexate, SD = standard deviation

a. Patients were naïve to MTX or received no more than 3 weekly MTX doses
b. Patients had inadequate response to MTX
c. Patients who had an inadequate response to csDMARDs; patients with prior exposure to at most one bDMARD were eligible (up to 20% of total number of patients) if they had either limited exposure (<3 months) or had to discontinue the bDMARD due to intolerability
d. Patients who had an inadequate response to MTX; patients with prior exposure to at most one bDMARD (except adalimumab) were eligible (up to 20% of total study number of patients) if they had either limited exposure (<3 months) or had to discontinue the bDMARD due to intolerability
e. Patients who had an inadequate response or intolerance to at least one bDMARD
f. Years since RA diagnosis
Study I (M13-545) was a 48-week trial in 947 patients with moderately to severely active rheumatoid arthritis who were naïve to methotrexate (MTX). Patients received RINVOQ 15 mg or upadacitinib 30 mg once daily or MTX as monotherapy. At Week 26, non-responding patients on upadacitinib could be rescued with the addition of MTX, while patients on MTX could be rescued with the addition of blinded RINVOQ 15 mg or upadacitinib 30 mg once daily. The primary endpoint was the proportion of patients who achieved an ACR50 response at Week 12. Key secondary endpoints included disease activity score (DAS28-CRP) ≤3.2 at Week 12, DAS28-CRP <2.6 at Week 24, change from baseline in Health Assessment Questionnaire – Disability Index (HAQ-DI) at Week 12, and change from baseline in van der Heijde-modified total Sharp Score (mTSS) at Week 24.

Study II (M15-555) was a 14-week monotherapy trial in 648 patients with moderately to severely active rheumatoid arthritis who had an inadequate response to MTX. Patients received RINVOQ 15 mg or upadacitinib 30 mg once daily monotherapy or continued their stable dose of MTX monotherapy. At Week 14, patients who were randomized to MTX were advanced to RINVOQ 15 mg or upadacitinib 30 mg once daily monotherapy in a blinded manner based on predetermined assignment at baseline. The primary endpoint was the proportion of patients who achieved an ACR20 response at Week 14. Key secondary endpoints included DAS28-CRP ≤3.2, DAS28-CRP <2.6, and change from baseline in HAQ-DI at Week 14.

Study III (M13-549) was a 12-week trial in 661 patients with moderately to severely active rheumatoid arthritis who had an inadequate response to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). Patients received RINVOQ 15 mg or upadacitinib 30 mg once daily or placebo added to background csDMARD therapy. At Week 12, patients who were randomized to placebo were advanced to RINVOQ 15 mg or upadacitinib 30 mg once daily in a blinded manner based on pre-determined assignment at baseline. The primary endpoint was the proportion of patients who achieved an ACR20 response at Week 12. Key secondary endpoints included DAS28-CRP ≤3.2, DAS28-CRP <2.6, and change from baseline in HAQ-DI at Week 12.

Study IV (M14-465) was a 48-week trial in 1629 patients with moderately to severely active rheumatoid arthritis who had an inadequate response to MTX. Patients received RINVOQ 15 mg once daily, adalimumab, or placebo added to background MTX. From Week 14, non-responding patients on RINVOQ 15 mg could be rescued to adalimumab in a blinded manner, and non-responding patients on adalimumab or placebo could be rescued to RINVOQ 15 mg in a blinded manner. At Week 26, all patients randomized to placebo were switched to RINVOQ 15 mg once daily in a blinded manner. The primary endpoint was the proportion of patients who achieved an ACR20 response at Week 12 versus placebo. Key secondary endpoints versus placebo included DAS28-CRP ≤3.2, DAS28-CRP <2.6, change from baseline in HAQ-DI at Week 12, and change from baseline in mTSS at Week 26.

Study V (M13-542) was a 12-week trial in 499 patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to biologic DMARDs. Patients received RINVOQ 15 mg or upadacitinib 30 mg once daily or placebo added to background csDMARD therapy. At Week 12, patients who were randomized to placebo were advanced to RINVOQ 15 mg or upadacitinib 30 mg once daily in a blinded manner based on pre-determined assignment at baseline. The primary endpoint was the proportion of patients who achieved an ACR20 response at Week 12. Key secondary endpoints included DAS28-CRP ≤3.2 and change from baseline in HAQ-DI at Week 12.
14.2 Study Results

Clinical Response

The percentages of patients treated with RINVOQ 15 mg achieving ACR20, ACR50, and ACR70 responses, DAS28-CRP <2.6 in all studies are shown in Table 7.

In all studies, patients treated with RINVOQ 15 mg, alone or in combination with csDMARDs, achieved significantly higher ACR20, ACR50, and ACR70 response rates compared to MTX monotherapy or placebo, respectively, at the primary efficacy time point, except for ACR70 in Study V (Table 7).

In Study IV, the percentage of patients achieving ACR20 responses by visit is shown in Figure 1. In Studies III and V, significantly higher ACR20 response rates were observed as early as Week 1 with RINVOQ 15 mg versus placebo.

Treatment with RINVOQ 15 mg, alone or in combination with csDMARDs, resulted in significantly greater improvements in the individual ACR components compared to placebo or MTX at the primary efficacy time point (Table 8).
<table>
<thead>
<tr>
<th>Study</th>
<th>Study I MTX-Naïve</th>
<th>Study II MTX-IR</th>
<th>Study III csDMARD-IR</th>
<th>Study IV csDMARD-IR</th>
<th>Study V bDMARD-IR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Monotherapy</td>
<td>Monotherapy</td>
<td>Background csDMARDs</td>
<td>Background MTX</td>
<td>Background csDMARDs</td>
</tr>
<tr>
<td>MTX</td>
<td>RINVOQ 15 mg % Δ (95% CI)</td>
<td>MTX</td>
<td>RINVOQ 15 mg % Δ (95% CI)</td>
<td>PBO</td>
<td>RINVOQ 15 mg % Δ (95% CI)</td>
</tr>
<tr>
<td>N</td>
<td>314</td>
<td>317</td>
<td>216</td>
<td>217</td>
<td>221</td>
</tr>
<tr>
<td>Week</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR 20%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12a/14b</td>
<td>54</td>
<td></td>
<td>76e 22 (14, 29)</td>
<td>41</td>
<td>68e 27 (18, 36)</td>
</tr>
<tr>
<td>24c/26d</td>
<td>59</td>
<td></td>
<td>79e 20 (13, 27)</td>
<td></td>
<td>67e 32 (27, 37)</td>
</tr>
<tr>
<td>ACR 50%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12a/14b</td>
<td>28</td>
<td></td>
<td>52e 24 (16, 31)</td>
<td>15</td>
<td>42e 27 (19, 35)</td>
</tr>
<tr>
<td>24c/26d</td>
<td>33</td>
<td></td>
<td>60e 27 (19, 34)</td>
<td></td>
<td>54e 33 (28, 38)</td>
</tr>
<tr>
<td>ACR 70%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12a/14b</td>
<td>14</td>
<td></td>
<td>33e 19 (12, 25)</td>
<td>3</td>
<td>23e 20 (14, 26)</td>
</tr>
<tr>
<td>24c/26d</td>
<td>19</td>
<td></td>
<td>45e 26 (19, 33)</td>
<td></td>
<td>35e 25 (21, 29)</td>
</tr>
</tbody>
</table>

Table 7. Proportion of Patients Achieving ACR Responses and DAS28-CRP <2.6
<table>
<thead>
<tr>
<th>Study</th>
<th>Study I MTX-Naive</th>
<th>Study II MTX-IR</th>
<th>Study III csDMARD-IR</th>
<th>Study IV&lt;sup&gt;h&lt;/sup&gt; MTX-IR</th>
<th>Study V bDMARD-IR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Monotherapy</td>
<td>Monotherapy</td>
<td>Background csDMARDs</td>
<td>Background MTX</td>
<td>Background csDMARDs</td>
</tr>
<tr>
<td>MTX</td>
<td>RINVOQ 15 mg %</td>
<td>MTX</td>
<td>PBO</td>
<td>PBO</td>
<td>ADA 40 mg</td>
</tr>
<tr>
<td></td>
<td>Δ (95% CI)</td>
<td>RINVOQ 15 mg %</td>
<td>RINVOQ 15 mg %</td>
<td>RINVOQ 15 mg %</td>
<td>RINVOQ 15 mg %</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Δ (95% CI)</td>
<td>Δ (95% CI)</td>
<td>Δ (95% CI)</td>
</tr>
<tr>
<td>N</td>
<td>314</td>
<td>317</td>
<td>216</td>
<td>217</td>
<td>221</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>221</td>
<td>221</td>
<td>651</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>651</td>
<td>651</td>
<td>327</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>169</td>
<td>164</td>
</tr>
<tr>
<td>Week</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DAS28-CRP &lt;2.6</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12&lt;sup&gt;a&lt;/sup&gt;/14&lt;sup&gt;b&lt;/sup&gt;</td>
<td>14</td>
<td>36&lt;sup&gt;e&lt;/sup&gt;</td>
<td>28&lt;sup&gt;e&lt;/sup&gt;</td>
<td>31&lt;sup&gt;e&lt;/sup&gt;</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22 (16, 29)</td>
<td>20 (13, 27)</td>
<td>21 (14, 28)</td>
<td>23 (19, 27)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>18</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>29&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>32 (17, 36)</td>
</tr>
<tr>
<td>24&lt;sup&gt;c&lt;/sup&gt;/26&lt;sup&gt;d&lt;/sup&gt;</td>
<td>19</td>
<td>48&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
<td>9</td>
<td>41&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>30 (23, 37)</td>
<td></td>
<td></td>
<td>32 (27, 36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>27</td>
</tr>
</tbody>
</table>

Abbreviations: ACR20 (or 50 or 70) = American College of Rheumatology ≥20% (or ≥50% or ≥70%) improvement; ADA = adalimumab; bDMARD = biologic disease-modifying anti-rheumatic drug; CRP = c-reactive protein; csDMARDs = conventional synthetic disease modifying anti-rheumatic drugs; DAS28 = Disease Activity Score 28 joints; IR = inadequate responder; MTX = methotrexate; PBO = placebo

Patients who discontinued randomized treatment, or had cross-over between randomized treatments, or were missing data at week of evaluation were imputed as non-responders in the analyses.

a. Study I, Study III, Study IV, Study V
b. Study II
c. Study I
d. Study IV
e. *p*≤0.001 RINVOQ 15 mg vs placebo or MTX comparison
f. The following comparisons for RINVOQ 15 mg vs placebo or MTX are included in multiplicity adjustment for overall type I error control: ACR20 at Week 12/14 in Study II, Study III, Study IV, and Study IV; ACR50 at Week 12 in Study I; DAS28-CRP <2.6 at Week 24 in Study I, and at Week 12/14 for Study II, Study III, and Study IV.
g. Not included in multiplicity adjustment for overall type I error control.
h. No conclusions can be drawn regarding the superiority of upadacitinib + MTX versus adalimumab + MTX.
### Table 8. Components of ACR Response (mean change from baseline)

<table>
<thead>
<tr>
<th>Study</th>
<th>Study I MTX-Naïve</th>
<th>Study II MTX-IR</th>
<th>Study III csDMARD-IR</th>
<th>Study IV MTX-IR</th>
<th>Study V bDMARD-IR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Monotherapy</td>
<td>Monotherapy</td>
<td>Background csDMARDs</td>
<td>Background MTX</td>
<td>Background csDMARDs</td>
</tr>
<tr>
<td>MTX</td>
<td>MTX 15 mg</td>
<td>MTX 15 mg</td>
<td>PBO</td>
<td>PBO</td>
<td>PBO 15 mg</td>
</tr>
<tr>
<td>N</td>
<td>314</td>
<td>216</td>
<td>217</td>
<td>221</td>
<td>651</td>
</tr>
</tbody>
</table>

#### Week

##### Number of tender joints (0-68)

<table>
<thead>
<tr>
<th>Time</th>
<th>MTX 15 mg</th>
<th>RINVOQ 15 mg</th>
<th>MTX 15 mg</th>
<th>RINVOQ 15 mg</th>
<th>PBO</th>
<th>RINVOQ 15 mg</th>
<th>ADA 40 mg</th>
<th>PBO</th>
<th>RINVOQ 15 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/14</td>
<td>-13</td>
<td>-17</td>
<td>-11</td>
<td>-15</td>
<td>-8</td>
<td>-14</td>
<td>-10</td>
<td>-16</td>
<td>-14</td>
</tr>
<tr>
<td>24/26</td>
<td>-16</td>
<td>-19</td>
<td></td>
<td></td>
<td></td>
<td>-9</td>
<td></td>
<td>-18</td>
<td>-15</td>
</tr>
</tbody>
</table>

##### Number of swollen joints (0-66)

<table>
<thead>
<tr>
<th>Time</th>
<th>MTX 15 mg</th>
<th>RINVOQ 15 mg</th>
<th>MTX 15 mg</th>
<th>RINVOQ 15 mg</th>
<th>PBO</th>
<th>RINVOQ 15 mg</th>
<th>ADA 40 mg</th>
<th>PBO</th>
<th>RINVOQ 15 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/14</td>
<td>-10</td>
<td>-12</td>
<td>-8</td>
<td>-11</td>
<td>-6</td>
<td>-9</td>
<td>-7</td>
<td>-11</td>
<td>-10</td>
</tr>
<tr>
<td>24/26</td>
<td>-12</td>
<td>-14</td>
<td></td>
<td></td>
<td></td>
<td>-6</td>
<td></td>
<td>-12</td>
<td>-11</td>
</tr>
</tbody>
</table>

##### Pain

<table>
<thead>
<tr>
<th>Time</th>
<th>MTX 15 mg</th>
<th>RINVOQ 15 mg</th>
<th>MTX 15 mg</th>
<th>RINVOQ 15 mg</th>
<th>PBO</th>
<th>RINVOQ 15 mg</th>
<th>ADA 40 mg</th>
<th>PBO</th>
<th>RINVOQ 15 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/14</td>
<td>-25</td>
<td>-36</td>
<td>-14</td>
<td>-26</td>
<td>-10</td>
<td>-30</td>
<td>-15</td>
<td>-25</td>
<td>-10</td>
</tr>
<tr>
<td>24/26</td>
<td>-28</td>
<td>-40</td>
<td></td>
<td></td>
<td></td>
<td>-19</td>
<td>-37</td>
<td>-32</td>
<td></td>
</tr>
</tbody>
</table>

##### Patient global assessment

<table>
<thead>
<tr>
<th>Time</th>
<th>MTX 15 mg</th>
<th>RINVOQ 15 mg</th>
<th>MTX 15 mg</th>
<th>RINVOQ 15 mg</th>
<th>PBO</th>
<th>RINVOQ 15 mg</th>
<th>ADA 40 mg</th>
<th>PBO</th>
<th>RINVOQ 15 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/14</td>
<td>-25</td>
<td>-35</td>
<td>-11</td>
<td>-23</td>
<td>-10</td>
<td>-30</td>
<td>-15</td>
<td>-24</td>
<td>-10</td>
</tr>
</tbody>
</table>

##### Disability Index (HAQ-DI)

<table>
<thead>
<tr>
<th>Time</th>
<th>MTX 15 mg</th>
<th>RINVOQ 15 mg</th>
<th>MTX 15 mg</th>
<th>RINVOQ 15 mg</th>
<th>PBO</th>
<th>RINVOQ 15 mg</th>
<th>ADA 40 mg</th>
<th>PBO</th>
<th>RINVOQ 15 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/14</td>
<td>-0.5</td>
<td>-0.8</td>
<td>-0.3</td>
<td>-0.7</td>
<td>-0.3</td>
<td>-0.6</td>
<td>-0.5</td>
<td>-0.2</td>
<td>-0.4</td>
</tr>
<tr>
<td>24/26</td>
<td>-0.6</td>
<td>-0.9</td>
<td></td>
<td></td>
<td></td>
<td>-0.3</td>
<td>-0.7</td>
<td>-0.6</td>
<td></td>
</tr>
</tbody>
</table>

##### Physician global assessment

<table>
<thead>
<tr>
<th>Time</th>
<th>MTX 15 mg</th>
<th>RINVOQ 15 mg</th>
<th>MTX 15 mg</th>
<th>RINVOQ 15 mg</th>
<th>PBO</th>
<th>RINVOQ 15 mg</th>
<th>ADA 40 mg</th>
<th>PBO</th>
<th>RINVOQ 15 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>24/26</td>
<td>-45</td>
<td>-50</td>
<td></td>
<td></td>
<td></td>
<td>-27</td>
<td>-45</td>
<td>-41</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Study I MTX-Naïve</td>
<td>Study II MTX-IR</td>
<td>Study III csDMARD-IR</td>
<td>Study IV MTX-IR</td>
<td>Study V bDMARD-IR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------------</td>
<td>----------------</td>
<td>----------------------</td>
<td>----------------</td>
<td>------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Monotherapy</td>
<td>Monotherapy</td>
<td>Background csDMARDs</td>
<td>Background MTX</td>
<td>Background csDMARDs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MTX</td>
<td>RINVOQ 15 mg</td>
<td>MTX</td>
<td>PBO</td>
<td>RINVOQ 15 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>314</td>
<td>317</td>
<td>216</td>
<td>217</td>
<td>221</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>651</td>
<td>651</td>
<td>327</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>169</td>
<td>164</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Week</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>hsCRP (mg/L)</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>12&lt;sup&gt;b&lt;/sup&gt;/14&lt;sup&gt;c&lt;/sup&gt;</td>
<td>-10.6</td>
<td>-17.5&lt;sup&gt;h&lt;/sup&gt;</td>
<td>-1.1</td>
<td>-10.2&lt;sup&gt;h&lt;/sup&gt;</td>
<td>-0.4</td>
<td>-10.1&lt;sup&gt;h&lt;/sup&gt;</td>
</tr>
<tr>
<td>24&lt;sup&gt;d&lt;/sup&gt;/26&lt;sup&gt;e&lt;/sup&gt;</td>
<td>-11.6</td>
<td>-18.4&lt;sup&gt;h&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ACR = American College of Rheumatology; ADA = adalimumab; bDMARD = Biologic disease-modifying anti-rheumatic drug; CRP = c-reactive protein; csDMARDs = conventional synthetic disease-modifying anti-rheumatic drugs; HAQ-DI = Health Assessment Questionnaire Disability Index; IR = inadequate responder; MTX = methotrexate; PBO = placebo

- Data shown are least square (LS) means of change from baseline
- Study I, Study III, Study IV, Study V
- Study II, primary efficacy time point is at Week 14
- Study I
- Study IV
- Visual analog scale: 0 = best, 100 = worst
- Health Assessment Questionnaire-Disability Index: 0=best, 3=worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. Data shown are the within group LS means of change from baseline.
- p≤0.001 RINVOQ 15 mg vs placebo or MTX comparison
Figure 1. Percent of Patients Achieving ACR20 in Study IV

Abbreviations: ACR20 = American College of Rheumatology ≥20% improvement; MTX = methotrexate
Patients who discontinued randomized treatment, or were missing ACR20 results, or were lost-to-follow-up or withdrawn from the study were imputed as non-responders.

In Study I and Study IV, a higher proportion of patients treated with RINVOQ 15 mg alone or in combination with MTX, achieved DAS28-CRP <2.6 compared to MTX or placebo at the primary efficacy time point (Table 9).
### Table 9. Proportion of Patients with DAS28-CRP Less Than 2.6 with Number of Residual Active Joints at Primary Efficacy Time Point

<table>
<thead>
<tr>
<th></th>
<th>Study I</th>
<th>Study IV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MTX</td>
<td>RINVOQ 15 mg</td>
</tr>
<tr>
<td></td>
<td>N = 314</td>
<td>N = 317</td>
</tr>
<tr>
<td>DAS28-CRP Less Than 2.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proportion of responders at Week 12 (n)</td>
<td>14% (43)</td>
<td>36% (113)</td>
</tr>
<tr>
<td>Of responders, proportion with 0 active joints (n)</td>
<td>51% (22)</td>
<td>45% (51)</td>
</tr>
<tr>
<td>Of responders, proportion with 1 active joint (n)</td>
<td>35% (15)</td>
<td>23% (26)</td>
</tr>
<tr>
<td>Of responders, proportion with 2 active joints (n)</td>
<td>9% (4)</td>
<td>17% (19)</td>
</tr>
<tr>
<td>Of responders, proportion with 3 or more active joints (n)</td>
<td>5% (2)</td>
<td>15% (17)</td>
</tr>
</tbody>
</table>

|                     | MTX     | RINVOQ 15 mg |
|                     | N = 651 | N = 651  |
| DAS28-CRP Less Than 2.6 |         |           |
| Proportion of responders at Week 12 (n) | 6% (40) | 29% (187) |
| Of responders, proportion with 0 active joints (n) | 60% (24) | 48% (89) |
| Of responders, proportion with 1 active joint (n) | 20% (8) | 23% (43) |
| Of responders, proportion with 2 active joints (n) | 15% (6) | 13% (25) |
| Of responders, proportion with 3 or more active joints (n) | 5% (2) | 16% (30) |

Abbreviations: CRP = C-reactive protein; DAS28 = Disease Activity Score 28 joints; MTX = methotrexate; PBO = placebo; IR = inadequate responder

### Radiographic response

Inhibition of progression of structural joint damage was assessed using the modified Total Sharp Score (mTSS) and its components, the erosion score, and joint space narrowing score at Week 26 in Study IV and Week 24 in Study I. The proportion of patients with no radiographic progression (mTSS change from baseline ≤0) was also assessed.

In Study IV, treatment with RINVOQ 15 mg resulted in significantly greater inhibition of the progression of structural joint damage compared to placebo at Weeks 26 (Table 10). Analyses of erosion and joint space narrowing scores were consistent with overall results. In this study, 76% of patients in the placebo plus MTX group experienced no radiographic progression at Week 26 compared to 84% of patients treated with RINVOQ 15 mg.

In Study I, treatment with RINVOQ 15 mg monotherapy resulted in significantly greater inhibition of the progression of structural joint damage compared to MTX monotherapy at Week 24 (Table 10). Analyses of erosion and joint space narrowing scores were consistent with overall results. In this study, 78% of the patients in the MTX monotherapy group experienced no radiographic progression at Week 24 compared to 88% of the patients treated with RINVOQ 15 mg monotherapy.
Table 10. Radiographic Changes

<table>
<thead>
<tr>
<th>Study</th>
<th>Study I MTX-Naïve</th>
<th>Study IV MTX-IR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Monotherapy</td>
<td>Background MTX</td>
</tr>
<tr>
<td>Treatment Group</td>
<td>MTX</td>
<td>RINVOQ 15 mg Δ (95% CI)</td>
</tr>
<tr>
<td>Week</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Modified Total Sharps Score, mean change from baseline**

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>24b/26c</td>
<td>0.7</td>
<td>0.1f</td>
<td>0.9</td>
<td>0.2e</td>
</tr>
<tr>
<td></td>
<td>-0.5 (-0.9, -0.2)</td>
<td>-0.7 (-1.0, -0.4)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Erosion Score, mean change from baseline**

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>24b/26c</td>
<td>0.3</td>
<td>0.1e</td>
<td>0.4</td>
<td>0e</td>
</tr>
<tr>
<td></td>
<td>-0.3 (-0.4, -0.1)</td>
<td>-0.4 (-0.6, -0.2)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Joint Space Narrowing Score, mean change from baseline**

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>24b/26c</td>
<td>0.3</td>
<td>0.1g</td>
<td>0.6</td>
<td>0.2e</td>
</tr>
<tr>
<td></td>
<td>-0.2 (-0.4, -0.0)</td>
<td>-0.4 (-0.6, -0.2)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Proportion of patients with no radiographic progressiond**

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>24b/26c</td>
<td>77.7</td>
<td>87.5f</td>
<td>76.0</td>
<td>83.5f</td>
</tr>
<tr>
<td></td>
<td>9.8 (3.5, 16.2)</td>
<td>7.5 (3.1, 12.1)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ADA = adalimumab; IR = inadequate responder; MTX = methotrexate; PBO = placebo;
a. Analyses are based on linear extrapolation
b. Study I
c. Study IV
d. No progression defined as mTSS change ≤0
e. p≤0.001 RINVOQ 15 mg vs placebo or MTX comparison
f. p≤0.01 RINVOQ 15 mg vs placebo or MTX comparison
g. p≤0.05 RINVOQ 15 mg vs placebo or MTX comparison

Physical function response and health-related outcomes

Treatment with RINVOQ 15 mg, alone or in combination with csDMARDs, resulted in a significant improvement in physical function compared to all comparators (placebo, MTX, or adalimumab) as measured by HAQ-DI at Week 12/14 (Table 11).

In Studies II, III, and IV, treatment with RINVOQ 15 mg resulted in a significantly greater improvement in the mean duration of morning joint stiffness compared to placebo or MTX at Week 12/14.

Other health-related outcomes

Across all studies, patients receiving RINVOQ 15 mg experienced significantly greater improvement from baseline in physical component summary (PCS) score, mental component summary (MCS) scores, and in all 8 domains of the Short Form Health Survey (SF-36) compared to placebo in combination with csDMARDs or MTX monotherapy at Week 12/14.
Fatigue was assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue score (FACIT-F) in Studies I, III, and IV. Improvement in fatigue at Week 12 was observed in patients treated with RINVOQ 15 mg compared to patients on placebo in combination with csDMARDs MTX monotherapy.
<table>
<thead>
<tr>
<th>Study</th>
<th>MTX-Naïve</th>
<th>MTX-IR</th>
<th>csDMARD-IR</th>
<th>MTX-IR</th>
<th>bDMARD-IR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study I</td>
<td>MTX</td>
<td>RINVOQ</td>
<td>MTX</td>
<td>RINVOQ</td>
<td>PBO</td>
</tr>
<tr>
<td></td>
<td>314</td>
<td>317</td>
<td>216</td>
<td>217</td>
<td>221</td>
</tr>
<tr>
<td>Study II</td>
<td>MTX</td>
<td>RINVOQ</td>
<td>PBO</td>
<td>RINVOQ</td>
<td>ADA</td>
</tr>
<tr>
<td></td>
<td>651</td>
<td>651</td>
<td>327</td>
<td>169</td>
<td>164</td>
</tr>
<tr>
<td>Study III</td>
<td>csDMARD-IR</td>
<td>PBO</td>
<td>RINVOQ</td>
<td>15 mg</td>
<td>PBO</td>
</tr>
<tr>
<td>Study IV</td>
<td>MTX-IR</td>
<td>ADA</td>
<td>PBO</td>
<td>RINVOQ</td>
<td>15 mg</td>
</tr>
<tr>
<td>Study V</td>
<td>bDMARD-IR</td>
<td></td>
<td>PBO</td>
<td>RINVOQ</td>
<td>15 mg</td>
</tr>
</tbody>
</table>

**HAQ-DI (MCID) at Week 12**

<table>
<thead>
<tr>
<th>Change from Baseline&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Δ (95% CI)</th>
<th>HAQ-DI Responder Rates&lt;sup&gt;e&lt;/sup&gt; (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTX-Naïve</td>
<td>0.49</td>
<td>54</td>
</tr>
<tr>
<td>MTX-IR</td>
<td>-0.83&lt;sup&gt;d&lt;/sup&gt;</td>
<td>77&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>csDMARD-IR</td>
<td>-0.65&lt;sup&gt;d&lt;/sup&gt;</td>
<td>39</td>
</tr>
<tr>
<td>MTX-IR</td>
<td>-0.59&lt;sup&gt;d&lt;/sup&gt;</td>
<td>62&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>bDMARD-IR</td>
<td>-0.60&lt;sup&gt;d&lt;/sup&gt;</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>-0.31&lt;sup&gt;d&lt;/sup&gt; (0.37, -0.025)</td>
<td>67&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Study II</td>
<td>-0.28</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>-0.25</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>-0.49</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td>-0.17</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td>-0.39&lt;sup&gt;d&lt;/sup&gt; (0.34, -0.10)</td>
<td>27</td>
</tr>
</tbody>
</table>

**Abbreviations:** ADA = adalimumab; HAQ-DI = Health Assessment Questionnaire Disability Index; IR = inadequate responder; MCID = minimal clinically important difference; MTX = methotrexate; PBO = placebo

<sup>a</sup> Data shown are least squares (LS) mean
<sup>b</sup> Studies I, III, IV and V
<sup>c</sup> Study II
<sup>d</sup> p≤0.001 RINVOQ 15 mg vs placebo or MTX comparison
<sup>e</sup> Percentage of patients with an improvement from baseline ≥0.30
15. NON-CLINICAL TOXICOLOGY

General Toxicology (single and repeat-dose studies)

In nonclinical studies, decreases in circulating lymphocytes and cellularity of lymphoid tissues, as well as suppression of erythropoiesis, were observed in rats and dogs at clinically relevant doses. In the 39-week dog study, secondary effects related to immunosuppression-induced opportunistic infections, such as demodicosis (mange) in dogs, were observed at exposures approximately two times the expected exposure (AUC) at the maximum recommended human dose (MRHD) of 15 mg daily, but there were no decreases in circulating lymphocytes and cellularity of lymphoid tissues. Immunotoxicity evaluations in male and female rats revealed complete suppression of IgM and IgG antibody responses to an injected test antigen (keyhole limpet hemocyanin) at all upadacitinib dose levels (5-50 mg/kg/day) in juvenile animals, and a dose-dependent suppression of IgM and IgG responses at all dose levels (5-60 mg/kg/day) in adult rats. The magnitude of the decreases in antibody responses were greater than the decreases in lymphocyte count in rats. The findings in juvenile and adult rats indicated upadacitinib-related suppression of antibody responses, consistent with JAK inhibition.

Carcinogenicity

The carcinogenic potential of upadacitinib was evaluated in Sprague-Dawley rats and Tg.rasH2 mice. No evidence of tumorigenicity was observed in male or female rats that received upadacitinib for up to 101 weeks at oral doses up to 15 or 20 mg/kg/day, respectively (approximately 4 and 10 times the daily MRHD exposure at 15 mg on an AUC basis for males and female rats, respectively). No evidence of tumorigenicity was observed in male or female Tg.rasH2 mice that received upadacitinib for 26 weeks at oral doses up to 20 mg/kg/day, at which systemic exposures to upadacitinib were less than 3 times that of the MRHD of 15 mg daily.

Genotoxicity

Upadacitinib was not mutagenic or genotoxic based on the results of an in vitro bacterial mutagenicity assay (Ames assay), an in vitro chromosome aberration assay in human peripheral blood lymphocytes, and an in vivo male rat bone marrow micronucleus assay for gene mutations and chromosomal aberrations.

Reproductive and Developmental Toxicology

Upadacitinib was teratogenic in rats and rabbits when given at exposures of 1.6 and 15 times the MRHD of 15 mg daily (on an AUC basis at maternal oral doses of 4 mg/kg/day and 25 mg/kg/day, respectively).

In two rat embryofetal development studies, pregnant animals were dosed orally during the period of organogenesis from gestation day (GD) 6 to GD 17. Upadacitinib was teratogenic at all dose levels studied in rats except the lowest dose of 1.5 mg/kg/day at which systemic exposure to upadacitinib was below that (approximately 0.3 times) at the MRHD of 15 mg daily on an AUC basis. At maternal oral doses of 4, 5, 25, and 75 mg/kg/day, upadacitinib-related effects included an increase in two particular skeletal malformations (i.e., misshapen humerus and bent scapula) and, at 75 mg/kg/day (at an exposure of approximately 84 times the MRHD on an AUC basis), an increase in bent bones of the fore- and hind-limbs in the absence of maternal toxicity. Additionally, at 25 and 75 mg/kg/day, there was an increase in bent ribs, a skeletal variation, which was also considered upadacitinib-related.
In a rabbit embryofetal development study, pregnant animals were dosed orally during the period of organogenesis from GD 7 to GD 19. Upadacitinib was teratogenic when given at 25 mg/kg/day. Developmental effects observed at 25 mg/kg/day in rabbits included an increase in post-implantation losses, increases in total and early resorptions, lower fetal body weights, and increased incidence of cardiac malformations. In addition, maternal toxicity was evident in the 25 mg/kg/day dose group from body weight loss, lower food consumption, and the increased occurrence of aborted pregnancies. Systemic exposure to upadacitinib at the no-effect dose of 10 mg/kg/day was about twice that at the MRHD of 15 mg daily.

In a pre-/postnatal development study in rats, development of the offspring consequent to exposure of the mothers from implantation through lactation and weaning was tested. Because manifestations of effects induced during this period may be delayed, observations were continued through sexual maturity of the pups. Mothers were dosed orally from GD 6 to Lactation Day 20. Upadacitinib had no effects at any dose level (2.5, 5, and 10 mg/kg/day) in mothers or their offspring in behavioral or reproductive endpoints.

In a fertility and early embryonic development study in rats, upadacitinib had no effect on fertility at oral doses up to 50 mg/kg/day in males and 75 mg/kg/day in females. However, maintenance of pregnancy was adversely affected at oral doses of 25 and 75 mg/kg/day as demonstrated by dose related increases in fetal resorptions associated with post-implantation losses, which were attributed to the developmental/teratogenic effects of upadacitinib in rats. The 5 mg/kg/day dose was the no-effect dose for early embryonic development.
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PATIENT MEDICATION INFORMATION

**PrRINVOQ®**

**Upadacitinib extended-release tablets**

Read this carefully before you start taking RINVOQ and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about RINVOQ.

---

**Serious Warnings and Precautions**

**Serious Infections**
- You should not take RINVOQ if you have any kind of infection.
- RINVOQ is a medicine that affects your immune system. It can lower the ability of your body to fight infections. Examples of these types of infection are tuberculosis, shingles (herpes zoster) or cryptococcosis, or infections caused by other bacteria, fungi or viruses that can spread throughout your body.
- In some cases, these infections may lead to hospitalization or death.
- Most patients taking RINVOQ who developed these infections were also taking other medicines, such as methotrexate or corticosteroids. These medicines may have made it harder to fight infections.
- Contact your healthcare professional if you have:
  - fever, sweating, chills,
  - muscle aches,
  - cough,
  - shortness of breath,
  - coughing up blood,
  - weight loss,
  - warm, red, or painful skin or sores on your body,
  - diarrhea or stomach pain,
  - burning when you urinate or urinating more often than normal,
  - feeling very tired.
  These may be signs that you have an infection.
- Your healthcare professional will monitor you for the signs and symptoms of infection during and after your treatment with RINVOQ.

**Cancers**
Lymphoma and other cancers have been reported in patients treated with RINVOQ.

**Blood clots**
- Deep vein thrombosis (blood clots in the veins of your legs), pulmonary embolism (blood clots in the lungs) or arterial thrombosis (blood clot in an artery) have occurred in patients taking RINVOQ and other similar medications. These blood clots can be life-threatening and cause death.
- If you develop any signs or symptoms of a blood clot in your leg (such as swelling, pain or tenderness in the leg) or in your lung (such as sudden unexplained chest pain or shortness of breath) stop RINVOQ and seek immediate medical help.
What is RINVOQ used for?
RINVOQ is used to treat adults with rheumatoid arthritis when treatment with methotrexate has not worked well or was not tolerated well. RINVOQ may be taken alone or in combination with other medicines.

RINVOQ is not recommended for use in children and adolescents under 18 years of age.

How does RINVOQ work?
RINVOQ is a ‘Janus kinase’ (JAK) inhibitor. JAK is an enzyme in your body, which normally helps to turn on your immune system when you need it. The immune system then causes swelling and tenderness, which is called inflammation. In people with rheumatoid arthritis who experience inflammation and pain in their joints, RINVOQ will attach to the JAK enzyme to lower its activity. This can improve the signs and symptoms of rheumatoid arthritis and help to slow damage to your bone and joints.

What are the ingredients in RINVOQ?
Medicinal ingredient: upadacitinib (as upadacitinib hemihydrate)

Non-medicinal ingredients: colloidal silicon dioxide, ferrosferric oxide (E172), hypromellose, iron oxide red (E172), magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc, tartaric acid, and titanium dioxide. The tablets are gluten-free.

RINVOQ comes in the following dosage forms:
Extended-release tablets: 15 mg upadacitinib

Do not use RINVOQ if:
- you are allergic to upadacitinib or any of the other ingredients in RINVOQ.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take RINVOQ. Talk about any health conditions or problems you may have, including if you:
- have or have had tuberculosis (TB). You may need tests to check for TB before you are given RINVOQ. Tell your healthcare professional if you get a persistent cough, fever, night sweats and weight loss during RINVOQ treatment. These can be signs of TB.
- have had a herpes infection (shingles). This is because RINVOQ may allow it to come back. Tell your healthcare professional if you get a painful skin rash with blisters during RINVOQ treatment. These can be signs of shingles.
- have or have had liver problems or hepatitis B or C.
- have recently had or plan to have a vaccination (immunization). You should not be given certain types of vaccines while using RINVOQ.
- have or have had cancer. Your healthcare professional will decide if you can still be given RINVOQ.
- have high cholesterol.
- have or have had diverticulitis (inflammation in parts of your large intestine), or gastrointestinal perforation (tears in your stomach or intestine). Some people taking RINVOQ can get tears in their stomach or intestines. Patients taking medications called non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids or those who have diverticulitis are more likely to have a gastrointestinal perforation.
- have low blood cell counts. Treatment with RINVOQ can be associated with anemia (low red blood cells), neutropenia or lymphopenia (low white blood cells).
- have muscle pain and / or muscle weakness.
Other warnings you should know about:

Cancer
Lymphoma and other cancers, including skin cancer, have been reported in patients treated with RINVOQ. Your healthcare professional will monitor you for the signs of skin cancer.

Blood tests
You may need blood tests before you start RINVOQ. These tests may be repeated while you are taking RINVOQ. These will help your healthcare professional to know how RINVOQ is affecting your blood and how well your liver is working.

Pregnancy and breastfeeding
• If you are pregnant, think you may be pregnant or are planning to have a baby, ask your healthcare professional for advice before taking this medicine. You should not use RINVOQ if you are pregnant.
• Avoid becoming pregnant while taking RINVOQ. It may harm your unborn baby. Use effective birth control while you are taking RINVOQ, and for at least 4 weeks after your last dose of RINVOQ. If you become pregnant during this time, tell your healthcare professional right away.
• You should not use RINVOQ if you are breastfeeding. It is not known if RINVOQ passes into breast milk. You and your healthcare professional should decide if you will take RINVOQ or breastfeed. Talk to your healthcare professional about the best way to feed your baby while you are being treated with RINVOQ.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with RINVOQ:
• medications for fungal infections (such as ketoconazole, itraconazole, posaconazole or voriconazole).
• a medication to treat bacterial infections called clarithromycin.
• a medication to treat bacterial infections like TB called rifampicin.
• a medication to prevent seizures called phenytoin.
• medications that affect your immune system (such as azathioprine, cyclosporin, and tacrolimus).
• an herbal remedy used mainly for depression called St-John’s Wort (hypericum perforatum).
• products or juices containing grapefruit. Avoid eating or drinking any products or juices containing grapefruit while taking RINVOQ.

These products may affect the amount of RINVOQ in your blood.

How to take RINVOQ:
• Take exactly as your healthcare provider tells you.
• Take once per day with or without food.
• Swallow tablets whole with water at about the same time each day.
• Do NOT split, crush or chew the tablets.
• Do not change your dose.
• Do not stop taking RINVOQ without first talking with your healthcare provider.

How to open the bottle and puncture the foil:

RINVOQ tablets will be given to you in bottles. Each bottle is sealed with foil and then closed with a cap. The cap has a cutting tool that can be used to help you puncture the foil seal.
1. The cap of the RINVOQ bottle has a foil cutting tool.

2a. To remove the cap from the bottle, push down and (at the same time) turn the cap counterclockwise.

2b. Turn the cap over. Place the cutting tool near the edge of the foil seal.

3. Push down to make a hole in the foil. Move the cutting tool around the edge of the foil. This will cut the foil all the way around.

4. When you have taken your tablet, put the cap back on and close the bottle.

Usual dose: One (15 mg) tablet per day

Your healthcare professional may interrupt your treatment with RINVOQ if you have certain side effects.

Overdose:

If you think you have taken too much RINVOQ, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

Missed dose:

If you miss a dose of RINVOQ, take your dose as soon as you remember. However, do not take more than 1 tablet per day.

What are possible side effects from using RINVOQ?

These are not all the possible side effects you may feel when taking RINVOQ. If you experience any side effects not listed here, contact your healthcare professional.

• throat and nose infections
• cough
• headache
• nausea
- cold sores
- back pain

RINVOQ can cause abnormal blood test results. Your healthcare professional will decide when to perform blood tests and interpret the results.

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk to your healthcare professional</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td><strong>COMMON</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumonia (lung infection):</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Coughing, fever, fatigue</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>UNCOMMON</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bronchitis (inflammation in the lung): persistent cough with or without mucus, fatigue, shortness of breath</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Herpes Zoster (shingles):</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>painful skin rash with blisters and fever</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary embolism (blood clot in the lung): sharp chest pain, coughing up blood, sudden shortness of breath</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Deep vein thrombosis (blood clot in the deep veins of the leg or arm): swelling, pain, arm or leg may be warm to the touch and may appear red</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Anemia (low red blood cells):</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>shortness of breath, feeling very tired, pale skin, fast heartbeat, loss of energy, weakness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary tract infection:</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>difficulty or increased need to urinate, pain or burning sensation when peeing, pain in the pelvis or middle of the back, urine that is cloudy or bloody</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cellulitis (skin infection):</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>redness, swelling, painful skin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New cancers (skin and other organs)</td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>
### Serious side effects and what to do about them

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk to your healthcare professional</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Liver problems:</strong> yellowing of the skin or eyes, dark urine, abdominal pain, nausea, vomiting, loss of appetite, itching</td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td><strong>Oral candidiasis</strong> (thrush in the mouth): thick white patches in the mouth, tongue or on the throat, sore throat</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Gastrointestinal perforation</strong> (tear in the stomach or intestinal wall): abdominal pain, feeling sick, vomiting, constipation, fever</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Arterial thrombosis</strong> (blood clot in an artery): chest pain, shortness of breath, dizziness, face drooping on one side, weakness in one arm, slurred speech, limbs may become painful, skin on limb may be pale or blue in colour and cold</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Neutropenia, leukopenia or lymphocytopenia</strong> (low white blood cells): fever or infection, fatigue, aches and pains, flu-like symptoms, swollen lymph nodes, painful joints</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Increased Creatinine Phosphokinase</strong> (CPK; CPK is an enzyme found in the blood when there is muscle damage): muscle aches, pain or stiffness; muscle weakness</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Hypercholesterolemia</strong> (high cholesterol)</td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.
Reporting Side Effects
You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (www.canada.ca/en/health-canada/services/drugs-health-products/mefefect-canada/adverse-reaction-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:
Store between 2 and 25°C in the original bottle to protect from moisture. Keep out of reach and sight of children.

If you want more information about RINVOQ:

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (www.canada.ca/en/health-canada), the manufacturer’s website (www.abbvie.ca), or by calling 1-888-704-8271.

This leaflet was prepared by AbbVie Corporation.

Last Revised: December 23, 2019